

ISBN 978-81-986001-9-6

ENDOCRINOLOGY: PRINCIPLES AND CLINICAL INTEGRATION VOL - I

PAYAL CHANDAK · ASHVINI DHAVAL
SHEETAL LONDHE · RHUTA JOGALEKAR


OLYMPICK
PUBLISHER INDIA

<https://olympickpublisher.in/>

JUNE
2026

Endocrinology: Principles and Clinical Integration

Vol - I

2026

Payal Chandak · Ashvini Dhavale

Sheetal Londhe · Rhuta Jogalekar

Authors



Authors

Ms. Payal Subhash Chandak

Assistant Professor, Department of Zoology,
Mudhoji College, Phaltan.

Ms. Ashvini Pandurang Dhavale

Assistant Professor, Department of Zoology,
Mudhoji College, Phaltan.

Dr. Sheetal Dattatray Londhe

Assistant Professor, Department of Zoology,
Willingdon College (Autonomous), Sangli.

Mrs. Rhuta S. Jogalekar

Research Scholar,
Department of Zoology,
Willingdon College (Autonomous), Sangli.

DOI : <https://doi.org/10.5281/zenodo.20697080>

ISBN 978-81-986001-9-6

<https://olympickpublisher.in/>



contact@olympickpublisher.in

Registered Address: Olympick Publisher India 201, Shitole Empire Building,
New Sangvi, Haveli, Pune - 411027

© The Author(s) and Editor(s) (if applicable) hold an exclusive license from Olympick Publisher India. Any reproduction, distribution or transmission of this publication in any form requires prior written authorization from the publisher except when brief quotations are used in academic research or critical reviews.

At publication time the publisher, authors / editors made every possible effort to provide information and advice in this book which is both accurate and current. The authors/ editors give no expressed or implied warranties about the material's completeness or correctness and they accept no responsibility for mistakes or missing information.

When disposing of this product, please ensure proper paper recycling.

Contents

<i>Chapter – I</i> Introduction to Endocrinology	<i>1-14</i>
<i>Chapter – II</i> Mechanisms of Hormone Action	<i>15-23</i>
<i>Chapter – III</i> Hypothalamus–Pituitary Axis and Control Systems	<i>24-35</i>
<i>Chapter – IV</i> Thyroid and Parathyroid Physiology and Pathology	<i>36-44</i>
<i>Chapter – V</i> Adrenal Glands and Stress Physiology	<i>45-57</i>
<i>Chapter – VI</i> Pancreatic Hormones and Metabolism	<i>58-71</i>
<i>Chapter – VII</i> Reproductive and Growth Endocrinology	<i>72-83</i>
<i>Chapter – VIII</i> Clinical Endocrinology and Emerging Concepts	<i>84-96</i>
References	
Appendices	

Chapter 1: Introduction to Endocrinology

1.1 Definition and scope of endocrinology

Endocrinology is the branch of biology and medicine that studies hormones, endocrine glands, and the disorders associated with abnormal hormone action. It deals with how chemical messengers, called hormones are produced, released, carried in the blood and regulated, and how they influence different cells, tissues, and organs to maintain physiological balance in the body. Endocrinology is therefore closely linked with physiology, biochemistry, and clinical medicine.

The word “endocrine” comes from the Greek words endo, meaning within, and krinein, meaning to secrete. Endocrine glands are ductless glands that release their secretions directly into the bloodstream rather than through a duct. Major endocrine glands include the hypothalamus, pituitary, thyroid, parathyroid, adrenal glands, pancreas, and gonads. In addition, organs such as the brain, liver, kidney, adipose tissue, and gastrointestinal tract also produce and respond to hormones or hormone-like substances, which broadens the scope of endocrinology.

The scope of endocrinology ranges from the molecular level to the whole organism. It covers processes such as growth and development, metabolism of carbohydrates, fats, and proteins, regulation of water and electrolyte balance, reproductive function, stress responses, and control of circadian rhythms. Endocrinology also includes the study of endocrine diseases such as diabetes mellitus, thyroid disorders, adrenal insufficiency, pituitary dysfunction, and reproductive endocrinopathies.

Modern endocrinology extends beyond classical glands and includes the role of obesity, metabolic syndrome, endocrine-disrupting chemicals, and the interaction between hormones, the immune system and behaviour. In teaching and research, it integrates cell biology, molecular genetics, and clinical practice to understand both normal hormone function and the mechanisms of disease. This section provides a basic definition and outline of the scope of endocrinology, which will serve as a foundation for the detailed discussion of individual endocrine systems in the following chapters of this book.

1.2 Historical developments in endocrinology

Endocrinology as a scientific discipline has its roots in ancient observations on body functions, but it began to take shape as a distinct field in the late 19th and early 20th centuries. Early physicians and scientists noticed that removing certain glands caused specific and predictable changes in the body, which suggested that these organs were producing chemical substances that influenced distant organs through the blood.

One of the earliest milestones was the discovery of the role of the thyroid gland in metabolism. Observations on patients with goiter and myxedema led to the idea that the thyroid produces a substance essential for normal growth and energy balance. Later, isolation and characterization of thyroid hormones helped to establish the concept of endocrine control of metabolism.

The adrenal glands were also studied early because their removal was found to be fatal. Experiments showed that adrenal extracts could restore normal function in animals that had lost their adrenal glands, indicating the presence of vital hormones such as corticosteroids and catecholamines. This work laid the foundation for understanding stress physiology and the hypothalamic–pituitary–adrenal axis.

The pituitary gland attracted attention when researchers observed that its removal caused severe disturbances in growth, reproduction, and water balance. Studies on pituitary extracts led to the identification of hormones such as growth hormone, prolactin, and gonadotropins. The discovery of antidiuretic hormone and oxytocin from the posterior pituitary further clarified how neural and endocrine systems are interconnected.

Insulin was discovered in the 1920s when scientists found that a substance from the pancreas could lower blood glucose and prevent the symptoms of diabetes. This breakthrough transformed diabetes from a fatal disease into a treatable condition and demonstrated the powerful therapeutic potential of hormones. The subsequent discovery of glucagon and other pancreatic hormones expanded understanding of carbohydrate and energy metabolism.

Work on sex hormones also progressed rapidly. Researchers identified substances from the ovaries and testes that controlled secondary sexual characters, menstrual cycles, and

spermatogenesis. The isolation of estrogen, progesterone, and testosterone helped to explain the endocrine control of reproduction and development.

Over time, advances in biochemistry, molecular biology, and immunology allowed scientists to characterize hormone structures, receptors, and signaling mechanisms. These developments turned endocrinology into a modern, molecular-level science, while still remaining closely tied to clinical medicine. The history of endocrinology, therefore, reflects a steady movement from whole-organ observations to cellular and molecular mechanisms, forming the basis for current teaching and research in the field.

1.3 Overview of the endocrine system and major endocrine glands


The endocrine system is a network of glands and specialized cells that produce hormones to regulate various physiological processes in the body. Unlike exocrine glands, which release their secretions through ducts onto surfaces or into cavities, endocrine glands are ductless and release hormones directly into the bloodstream. These hormones travel to distant target organs, where they bind to specific receptors and elicit a physiological response.

The major endocrine glands include the hypothalamus, pituitary gland, thyroid gland, parathyroid glands, adrenal glands, pancreas, gonads, and, in females, the placenta during pregnancy. In addition, several other organs such as the brain, liver, kidney, adipose tissue, heart, and gastrointestinal tract also produce and secrete hormone-like substances, which contribute to the complexity and integration of the endocrine system.

The hypothalamus is located in the brain and serves as a key link between the nervous system and the endocrine system. It produces releasing and inhibiting hormones that control the secretion of hormones from the anterior pituitary. The pituitary gland, often called the “master gland,” is divided into anterior and posterior lobes and regulates many other endocrine glands through its trophic hormones.

The hypothalamus is located in the brain and serves as a key link between the nervous system and the endocrine system. It produces releasing and inhibiting hormones that control the secretion of hormones from the anterior pituitary. The pituitary gland, often called the “master gland,” is divided into anterior and posterior lobes and regulates many other endocrine glands through its trophic hormones.

Figure 1. : Endocrine System Overview Showing Major Glands of the Human Body



The thyroid gland is situated in the neck and produces thyroid hormones that regulate metabolism, growth, and development. The small parathyroid glands, embedded in or near the thyroid, secrete parathyroid hormone, which maintains calcium and phosphate balance. The adrenal glands, located on top of the kidneys, consist of an outer cortex and an inner medulla; the cortex secretes steroid hormones such as cortisol and aldosterone, while the medulla produces catecholamines like epinephrine and norepinephrine.

The pancreas has both exocrine and endocrine functions. Its endocrine portion is formed by the islets of Langerhans, which secrete insulin and glucagon to regulate blood glucose levels. The gonads, the testes in males and ovaries in females, produce sex steroids and gametes and play a central role in reproductive function and secondary sexual

characteristics. The placenta, during pregnancy, produces hormones that support fetal development and maintain pregnancy.

The endocrine system does not work in isolation; it constantly interacts with the nervous and immune systems to coordinate responses to internal and external stimuli. Together, these systems maintain homeostasis, adapt the body to changing conditions, and support growth, reproduction, and survival. Understanding the basic organization of the endocrine system and the functions of its major glands provides a foundation for studying individual hormones and their roles in health and disease.


TABLE 1.1: Major Endocrine Glands & Hormones

Gland	Location	Main Hormones	Key Function
Hypothalamus	Brain	TRH, CRH, GnRH	Controls pituitary
Pituitary (Anterior)	Base of brain	TSH, ACTH, GH, FSH/LH	Master gland
Thyroid	Neck	T4, T3, Calcitonin	Metabolism
Parathyroid	Near thyroid	PTH	Calcium balance
Adrenal Cortex	Above kidneys	Cortisol, Aldosterone	Stress, salt balance
Pancreas (Islets)	Abdomen	Insulin, Glucagon	Blood glucose
Gonads	Pelvis	Estrogen, Testosterone	Reproduction

1.4 Major endocrine glands and their hormones

The endocrine system functions through a group of specialized glands that produce specific hormones. Each gland has a distinct location and role, but they are closely interconnected so that the activity of one gland influences the others. Below is a brief description of the major endocrine glands and the principal hormones they secrete.

Figure 1.2: Hypothalamus–Pituitary Axis
Showing Control of the Master Gland



The hypothalamus is a small region in the brain that produces releasing and inhibiting hormones such as thyrotropin-releasing hormone (TRH), corticotropin-releasing hormone (CRH), gonadotropin-releasing hormone (GnRH), and growth hormone–releasing hormone (GHRH). These hormones regulate the secretion of pituitary hormones, thereby influencing the thyroid, adrenal, gonadal, and growth axes.

The pituitary gland lies below the hypothalamus and is divided into the anterior (adenohypophysis) and posterior (neurohypophysis) lobes. The anterior pituitary secretes hormones such as growth hormone (GH), thyroid-stimulating hormone (TSH), adrenocorticotrophic hormone (ACTH), prolactin, follicle-stimulating hormone (FSH), and luteinizing hormone (LH). The posterior pituitary releases antidiuretic hormone (ADH, or vasopressin) and oxytocin, which are actually produced in the hypothalamus and transported to the pituitary.

The thyroid gland is located in the neck and produces the iodine-containing hormones thyroxine (T₄) and triiodothyronine (T₃). These hormones regulate basal metabolic rate, heat production, growth, and development of the nervous system. The thyroid also secretes calcitonin, which plays a minor role in calcium regulation.

The parathyroid glands are four small structures embedded in or near the thyroid. They secrete parathyroid hormone (PTH), which controls calcium and phosphate levels in the blood by acting on bone, kidneys, and the intestine. PTH helps raise blood calcium and lower blood phosphate to maintain mineral balance.

The adrenal glands sit on top of the kidneys and have two distinct parts. The adrenal cortex produces steroid hormones: glucocorticoids (mainly cortisol), which regulate metabolism and stress responses; mineralocorticoids (such as aldosterone), which control sodium and potassium balance and blood pressure; and adrenal androgens, which contribute to sex steroid production. The adrenal medulla secretes the catecholamines epinephrine and norepinephrine, which prepare the body for “fight-or-flight” responses.

The pancreas has both exocrine and endocrine portions. The endocrine part consists of clusters of cells called the islets of Langerhans. The beta cells of the islets secrete insulin, which lowers blood glucose by promoting its uptake and storage in tissues. The alpha cells secrete glucagon, which raises blood glucose by stimulating glycogen breakdown and glucose production in the liver. Other islet cells produce somatostatin and pancreatic polypeptide, which modulate insulin and glucagon secretion and gastrointestinal functions.

The gonads include the testes in males and ovaries in females. The testes produce testosterone and other androgens, which control male sexual development, secondary sexual characteristics, and spermatogenesis. The ovaries produce estrogens and progesterone, which regulate the menstrual cycle, prepare the uterus for pregnancy, and support fetal development. The gonads also secrete inhibin and activin, which modulate gonadotropin release.

In pregnant females, the placenta becomes an important endocrine organ. It secretes hormones such as human chorionic gonadotropin (hCG), human placental lactogen (HPL), progesterone, and estrogen, which maintain pregnancy, support fetal growth, and prepare the maternal body for childbirth.

Many other tissues also contribute to endocrine function. For example, adipose tissue secretes leptin and adiponectin, which influence appetite and metabolism; the kidney produces erythropoietin and renin; and the heart releases atrial natriuretic peptide (ANP). This broad distribution of hormone-producing cells shows that the endocrine system is widely integrated throughout the body and plays a central role in maintaining stability and coordinating complex physiological responses.

1.5 Endocrine system vs nervous system: integration and crosstalk

The endocrine system and the nervous system are two major regulatory systems that coordinate activities in the body, but they differ in their mode of communication, speed of action, and duration of effects. The nervous system uses electrical impulses and neurotransmitters to transmit signals rapidly along nerve fibers, resulting in quick, short-lived responses such as muscle contraction or reflexes. In contrast, the endocrine system uses hormones released into the bloodstream, which travel more slowly but produce longer-lasting effects on target organs.

Despite these differences, the two systems are closely integrated and constantly interact. The hypothalamus, for example, is a brain region that receives neural inputs and also functions as an endocrine organ by producing hormones that control the pituitary gland. This connection allows neural signals—such as those related to stress, emotions, or environmental changes—to influence hormone secretion and thereby alter metabolic, reproductive, or immune functions.

Many physiological responses involve both systems working together. During stress, the nervous system activates the sympathetic division, leading to rapid release of epinephrine and norepinephrine from the adrenal medulla. At the same time, the hypothalamic–pituitary–adrenal axis is activated, resulting in the slower but sustained release of cortisol. This combined action prepares the body for immediate threats while maintaining energy supply and immune modulation over a longer period.

Similarly, in reproduction, neural signals from the brain influence the secretion of gonadotropin-releasing hormone, which in turn regulates gonadotropin release and sex steroid production. Behavior, sleep-wake cycles, and feeding are also controlled by interactions between neural circuits and hormones such as melatonin, leptin, and ghrelin. These crosstalk mechanisms ensure that the body responds in a coordinated and adaptive manner to internal and external changes.

Understanding the relationship between the endocrine and nervous systems is essential for appreciating how the body maintains homeostasis and how disturbances in one system can affect the other. This integration forms the basis for many clinical conditions, including stress-related disorders, sleep disturbances, appetite disorders, and certain psychiatric and metabolic diseases. In this chapter, the focus remains on the endocrine system, but recognition of its close ties with the nervous system helps to place hormone actions in a broader physiological context.

1.6 Classes of hormones: peptides, steroids, and amines

Hormones can be grouped into three main chemical classes based on their molecular structure: peptide and protein hormones, steroid hormones, and amine hormones. Each class has distinct features related to synthesis, storage, transport, and mode of action.

Peptide and protein hormones are made up of amino acid chains. Small peptides include hormones such as antidiuretic hormone, oxytocin, and many hypothalamic releasing hormones. Larger protein hormones include insulin, growth hormone, and the pituitary trophic hormones such as TSH, ACTH, FSH, and LH. These hormones are synthesized as larger precursor molecules, processed in the endoplasmic reticulum and Golgi apparatus, and stored in secretory granules before release. They are water-soluble, circulate freely in the blood, and bind to receptors on the surface of target cells to initiate intracellular signaling.

Steroid hormones are derived from cholesterol and include cortisol, aldosterone, testosterone, estrogen, and progesterone. Because they are lipid-soluble, steroid hormones are not stored in large amounts in glands; instead, they are synthesized on demand from precursor molecules. In the blood, they bind to carrier proteins, which protect them from degradation and regulate their availability to tissues. Steroid hormones cross the cell membrane and bind to intracellular or nuclear receptors, forming hormone–receptor complexes that directly regulate gene transcription and protein synthesis in target cells.

Amine hormones are derived from the amino acid tyrosine. This group includes thyroid hormones (thyroxine and triiodothyronine) and the catecholamines epinephrine and norepinephrine. Thyroid hormones are structurally similar to steroids in that they bind to nuclear receptors and regulate gene expression, whereas catecholamines act more like peptide hormones by binding to cell surface receptors and triggering rapid intracellular signaling events. Because of their different chemical properties, thyroid hormones have long-lasting effects, while catecholamines act quickly but for a short duration.

These structural differences also influence how hormones are regulated. Peptide hormones are often controlled by feedback mechanisms that act at the level of gene expression and secretion, whereas steroid and thyroid hormones are regulated through synthesis rate, carrier-protein binding, and receptor sensitivity. Understanding the main classes of hormones helps to explain why some hormones exert rapid effects at the

membrane level while others produce slower, long-term changes in cell function and gene expression.

TABLE 1.2: Main classes of hormones and their features

Hormone class	Chemical nature	Solubility	Main site of action	Examples
Peptide/protein	Chains of amino acids	Water-soluble	Cell-surface receptors	Insulin, glucagon, TSH, ACTH
Steroid	Derived from cholesterol	Lipid-soluble	Intracellular/nuclear receptors	Cortisol, aldosterone, estradiol
Amine	Derived from tyrosine	Variable	Cell surface or nuclear receptors	Thyroxine, epinephrine

TABLE 1.3: Hormone Classes Comparison

Class	Examples	Solubility	Receptor Location	Action Speed
Peptide/Protein	Insulin, TSH, GH	Water-soluble	Cell surface	Fast (seconds)
Steroid	Cortisol, Estrogen	Lipid-soluble	Nuclear	Slow (hours)
Amine	T4/T3, Epinephrine	Variable	Surface/Nuclear	Variable

1.7 Modes of hormone action: endocrine, paracrine, and autocrine

Hormones can influence target cells in different ways depending on the distance between the secreting cell and the responding cell. The three main modes of hormone action are endocrine, paracrine, and autocrine. In some cases, hormones also act in an intracrine manner inside the cell that produces them.


Endocrine action is the classical mode of hormone action. In this mode, hormones are secreted by endocrine glands into the bloodstream and travel to distant target organs or tissues. For example, thyroid hormones released by the thyroid gland circulate widely and affect metabolism in many organs, while insulin secreted by the pancreatic beta cells acts on the liver, muscle, and adipose tissue. Endocrine signaling is relatively slow but widespread, allowing coordinated regulation of body functions over long distances.

Paracrine action occurs when a hormone or signaling molecule acts locally on nearby cells without entering the general circulation. The hormone diffuses through the interstitial fluid and affects only adjacent cells that express the appropriate receptors. Examples include somatostatin released by delta cells in the pancreatic islets, which inhibits the secretion of insulin and glucagon from neighboring beta and alpha cells, and various growth factors acting within a tissue to regulate cell growth and repair.

Autocrine action occurs when a cell secretes a substance that binds to receptors on its own surface, thereby regulating its own activity. Some cytokines, growth factors, and certain peptide hormones act in an autocrine manner to modulate cell proliferation, differentiation, or secretion. This mode of action allows cells to fine-tune their responses in a self-regulated way.

In addition, intracrine signaling refers to hormones that act inside the same cell that produces them, often after conversion into an active form, without being released into the extracellular space. This mechanism is seen in some steroid hormones, where conversion within the cell leads to local effects on gene expression.

Recognizing these different modes of hormone action helps to explain why some hormones have broad systemic effects while others act in a very localized and specific manner. Endocrine, paracrine, and autocrine mechanisms often work together to produce precise and coordinated responses in tissues and organs. In this chapter, the focus is mainly on endocrine hormones, but the concepts of paracrine and autocrine actions are important for understanding the full spectrum of hormonal regulation in the body.

**TABLE 1.2: Modes of hormone action**

Mode	Meaning	Example
Endocrine	Hormone released into blood and acts on distant target	TSH acting on thyroid
Paracrine	Hormone acts on nearby cells without entering general blood	Somatostatin inhibiting insulin in islets
Autocrine	Hormone acts on the same cell that produced it	Some growth factors acting on same cell type
Intracrine	Hormone acts inside the same cell, without being released	Some steroid hormones inside producing cell

1.8 Feedback mechanisms and homeostasis

The endocrine system maintains stability in the body through feedback mechanisms that regulate hormone secretion and action. These mechanisms ensure that hormone levels remain within a narrow range, allowing the body to respond appropriately to changes

while avoiding excessive or insufficient responses. The most common type of regulation is negative feedback, in which the effect of a hormone reduces its own secretion.

In a typical negative-feedback loop, a hormone acts on its target tissues and also on the gland or hypothalamic–pituitary axis that produces it, inhibiting further release. For example, thyroid-stimulating hormone (TSH) from the pituitary stimulates the thyroid gland to produce thyroxine (T4) and triiodothyronine (T3). When blood levels of T4 and T3 rise, they act on the pituitary and hypothalamus to suppress the secretion of TSH and thyrotropin-releasing hormone, thereby preventing overproduction of thyroid hormones. Similar negative-feedback arrangements operate in the hypothalamic–pituitary–adrenal axis and the hypothalamic–pituitary–gonadal axis.

In some cases, positive feedback also occurs, in which a hormone enhances its own secretion or the secretion of another hormone involved in a particular process. A classic example is the role of estrogen in the menstrual cycle: increasing estrogen levels from the developing follicle stimulate the release of luteinizing hormone (LH) from the pituitary, which in turn triggers ovulation. Once the peak of LH is reached, the system switches back to a negative-feedback mode.

Set points and homeostasis are central concepts in endocrinology. A set point refers to the desired level or range around which a physiological variable is maintained, such as blood glucose, calcium concentration, or body temperature. Hormones act as regulators that sense deviations from the set point and trigger corrective responses. For instance, insulin and glucagon regulate blood glucose around a set range, while parathyroid hormone and calcitonin maintain calcium balance.

These feedback systems allow the endocrine system to adapt to daily changes such as feeding, fasting, exercise, and stress. They also help to protect the body from extreme fluctuations that could damage cells and organs. Disturbances in feedback mechanisms can lead to endocrine disorders, such as overactivity of a gland (hyperfunction) or underactivity (hypofunction). Understanding feedback loops and the principle of homeostasis provides a framework for interpreting how hormones normally maintain balance and how their dysfunction gives rise to disease.

KEY CONCEPTS:

- ☒ **Endocrinology** = Study of hormones from ductless glands released directly into blood
- ☒ **7 Major glands:** Hypothalamus, Pituitary, Thyroid, Parathyroid, Adrenal, Pancreas, Gonads
- ☒ **3 Hormone classes:** Peptides (insulin), Steroids (cortisol), Amines (T4, epinephrine)
- ☒ **4 Action modes:** Endocrine (blood), Paracrine (local), Autocrine (self), Intracrine (intracellular)
- ☒ **Feedback loops:** Negative (TSH-T4 axis), Positive (LH surge ovulation)

- **Clinical correlation 1.1 Primary hypothyroidism**

35F: Fatigue, weight +8kg, cold intolerance

Labs: TSH 15 mIU/L ↑↑, FT4 0.6 ↓↓

Dx: Primary hypothyroidism

Rx: Levothyroxine 100µg OD

Chapter 2: Mechanisms of Hormone Action

2.1 Hormone synthesis and secretion

Hormone synthesis and secretion represent tightly regulated processes that differ according to the chemical class of the hormone and the functional characteristics of the endocrine cell. Each hormone is produced through a sequence of biosynthetic steps, followed by intracellular processing, storage (where applicable), and regulated release in response to specific physiological signals.

Peptide and protein hormones are initially synthesized as larger precursor molecules known as preprohormones on the rough endoplasmic reticulum. The signal peptide is cleaved to generate prohormones, which are then transported to the Golgi apparatus for post-translational modifications such as glycosylation and proteolytic cleavage. Within the trans-Golgi network, prohormones are packaged into membrane-bound secretory granules. In these granules, specific convertase enzymes cleave the prohormones into biologically active hormones and, in some cases, smaller peptide fragments. The mature hormones remain stored in secretory granules until an appropriate stimulus—such as membrane depolarization, ligand-receptor interaction, or elevation of intracellular calcium—triggers exocytosis and release into the interstitial space and subsequently into the bloodstream.

Steroid hormones are synthesized from cholesterol, which may be derived from circulating low-density lipoproteins or from intracellular synthesis. Cholesterol is transported into the mitochondria, where it is converted to pregnenolone by the enzyme cholesterol side-chain cleavage enzyme (P450_{scc}). Pregnenolone serves as the common precursor for all steroid hormones. Subsequent enzymatic reactions, occurring in both mitochondria and the endoplasmic reticulum, generate specific steroids such as glucocorticoids (e.g., cortisol), mineralocorticoids (e.g., aldosterone), and sex steroids (e.g., testosterone, estradiol, and progesterone). Because steroid hormones are lipid-soluble, they readily diffuse across the plasma membrane after synthesis and do not accumulate in large secretory granules. Their rate of secretion is therefore determined primarily by the activity of steroidogenic enzymes and the availability of cholesterol substrate.

Amine hormones are derived from the amino acid tyrosine. In the thyroid gland, thyroglobulin, a large glycoprotein, is synthesized in follicular cells and secreted into the follicular lumen, where iodination and coupling reactions yield thyroxine (T_4) and triiodothyronine (T_3). When thyroid-stimulating hormone (TSH) binds to its receptor on follicular cells, it triggers the re-endocytosis of thyroglobulin, its proteolytic processing in lysosomes, and the release of T_4 and T_3 into the circulation. In the adrenal medulla, tyrosine undergoes a series of enzymatic conversions to form epinephrine and norepinephrine. These catecholamines are stored in chromaffin granules and released by exocytosis in response to sympathetic nerve stimulation.

The regulation of hormone secretion operates at multiple levels, including gene transcription, translation, post-translational modification, enzyme activity, and intracellular signaling cascades. Many hormones are secreted in a pulsatile or circadian manner, reflecting the influence of hypothalamic inputs, other hormones, and external factors such as photoperiod, stress, and nutritional status. Understanding the molecular and cellular mechanisms underlying hormone synthesis and secretion is essential for elucidating normal endocrine physiology and for interpreting the pathophysiology of endocrine disorders, including hypo- and hypersecretory states.

TABLE 2.1: Hormone Synthesis Comparison

Hormone Type	Synthesis Site	Storage	Release Trigger	Example
Peptide	RER → Golgi → Granules	YES (granules)	Ca^{2+} , depolarization	Insulin, TSH
Steroid	Mitochondria + ER	NO	Enzyme activity	Cortisol, Estrogen
Amine (Thyroid)	Colloid → Lysosomes	YES (thyroglobulin)	TSH	T_4 , T_3

2.2 Transport of hormones in blood

Most hormones are secreted into the blood and must travel to their target organs. The way they move in the circulation depends on their chemical nature. Peptide and protein hormones are water-soluble and circulate freely in plasma, bound only weakly, if at all, to carrier proteins. Because they are not strongly bound, they are generally biologically active soon after secretion and are cleared from the blood relatively quickly by the liver and kidneys.

Steroid hormones and thyroid hormones are lipid-soluble and are largely transported bound to specific plasma proteins. Examples of these binding proteins include corticosteroid-binding globulin (CBG), sex hormone-binding globulin (SHBG), and thyroxine-binding globulin (TBG). Only a small fraction of these hormones circulates in the free, unbound form, but it is the free hormone that can diffuse into tissues and bind to receptors. The bound fraction acts as a reservoir, prolonging hormone half-life and buffering changes in total hormone concentration.

The balance between free and bound hormone is important in endocrine function. Changes in the concentration of binding proteins—due to liver disease, pregnancy, drugs, or other conditions—can alter free hormone levels and mimic or mask endocrine disorders. Thus, assessing hormone transport and binding is essential for accurate interpretation of hormone assays and for understanding hormone availability to target tissues.

2.3 Types of hormone receptors: cell surface and intracellular

Hormone receptors are specialized proteins that recognize and bind specific hormones, thereby initiating a cellular response. The location and structure of receptors depend on the chemical class of the hormone.

Cell surface receptors are used by water-soluble hormones such as peptide and protein hormones and catecholamines. These receptors are embedded in the plasma membrane and contain an extracellular hormone-binding domain and an intracellular domain that interacts with intracellular signaling molecules. When a hormone binds, it induces a conformational change that activates associated G-proteins, enzyme systems (such as tyrosine kinases), or ion channels. This leads to the generation of second messengers such


as cyclic AMP (cAMP), inositol trisphosphate (IP₃), diacylglycerol (DAG), or calcium, which relay the signal inside the cell.

TABLE 2.2: Receptor Types & Speed

Hormone Class	Receptor Location	Second Messengers	Action Time	Examples
Peptide	Cell Surface	cAMP, IP ₃ /DAG, Ca ²⁺	Seconds-Minutes	Glucagon, Insulin
Steroid/Thyroid	Nuclear	Gene transcription	Hours-Days	Cortisol, T3

Intracellular and nuclear receptors are used by steroid and thyroid hormones. Because these hormones are lipid-soluble, they diffuse across the plasma membrane and bind to receptors located in the cytoplasm or nucleus. The hormone–receptor complex then acts as a transcription factor, binding to specific hormone-response elements on DNA and regulating the expression of target genes. This mechanism produces slower but longer-lasting effects on protein synthesis and cell function.

The distinction between cell surface and intracellular receptors explains why some hormones act within seconds or minutes by modifying existing proteins, while others take hours or days by altering gene expression. Understanding receptor types and their mechanisms is fundamental for interpreting hormone actions and for designing drugs that modulate hormone signaling.



2.4 Signal transduction pathways: cAMP, IP₃–DAG, and others

Signal transduction is the process by which a hormone binding to its receptor is converted into an intracellular response. Different receptors activate different pathways, but several common mechanisms appear repeatedly in endocrinology.

The cAMP pathway is activated by many peptide hormones that bind to G-protein-coupled receptors. Hormone binding causes a stimulatory G-protein (Gs) to activate adenylyl cyclase, which converts ATP to cyclic AMP. cAMP then activates protein kinase A (PKA), which phosphorylates specific target proteins, altering their

activity and leading to metabolic, secretory, or contractile responses. An example is the action of glucagon on the liver, where cAMP–PKA signaling promotes glycogen breakdown and glucose production.

TABLE 2.3: Major Signaling Pathways

Pathway	Receptor	Key Messengers	Effects	Hormones
cAMP	GPCR (Gs)	cAMP → PKA	Glycogenolysis	Glucagon, TSH
IP ₃ /DAG	GPCR (Gq)	IP ₃ → Ca ²⁺ , DAG → PKC	Secretion	Vasopressin
RTK	Tyrosine Kinase	PI3K, MAPK	Glucose uptake	Insulin
JAK-STAT	Cytokine receptor	STAT → Nucleus	Gene expression	Growth hormone

The IP₃–DAG pathway is another major route. Here, hormone binding to certain G-protein-coupled receptors activates phospholipase C, which splits a membrane phospholipid into inositol trisphosphate (IP₃) and diacylglycerol (DAG). IP₃ releases calcium from intracellular stores, raising cytosolic calcium levels, while DAG activates protein kinase C (PKC). Together, calcium and PKC modulate enzyme activity, secretion, and gene expression in target cells. This pathway is important in responses such as vasoconstriction and certain hormone-induced cellular secretions.

Some hormone receptors have intrinsic tyrosine kinase activity, such as the insulin receptor. Hormone binding induces receptor dimerization and autophosphorylation, creating docking sites for intracellular signaling proteins. These proteins initiate cascades involving molecules such as IRS-1, PI3K, and MAP kinase, which regulate glucose uptake, protein synthesis, and cell growth.

Other pathways include the JAK–STAT system, used by some cytokines and hormones, where receptor-associated Janus kinases phosphorylate STAT proteins; these then translocate to the nucleus and regulate gene transcription. The choice of pathway affects the speed, duration, and specificity of hormone action and helps explain the diversity of endocrine responses in different tissues.

Table 2.4: Major hormone signal-transduction pathways

Pathway	Main hormone receptor type	Key second messengers	Example hormones
cAMP pathway	G-protein-coupled receptor (Gs)	cAMP, protein kinase A (PKA)	Glucagon, TSH, ACTH
IP ₃ –DAG pathway	G-protein-coupled receptor (Gq)	IP ₃ , DAG, Ca ²⁺ , protein kinase C	Vasoconstrictive hormones, some releasing hormones
Tyrosine kinase	Receptor with kinase activity	Phosphorylated proteins, PI3K	Insulin, growth factor receptors
Nuclear receptor	Intracellular/nuclear receptor	Altered gene expression	Cortisol, thyroid hormone, vitamin D

2.5 Receptor regulation and hormone sensitivity

The responsiveness of a target cell to a hormone depends not only on hormone concentration but also on the number and sensitivity of receptors and the efficiency of downstream signaling. Cells can adjust their sensitivity by changing receptor expression and function.

Up-regulation occurs when a cell increases the number of receptors in response to low hormone levels, making it more sensitive to the hormone. Down-regulation occurs when prolonged exposure to high hormone concentrations leads to a decrease in receptor number or function, reducing the cell's response and helping to prevent overstimulation. Mechanisms include receptor internalization, degradation, or decreased gene expression.

Cells may also change receptor sensitivity through desensitization, in which repeated or continuous hormone exposure reduces the magnitude of the response without necessarily reducing receptor number. This often involves phosphorylation of the receptor or

associated signaling proteins, which weakens signal transduction. At the same time, heterologous sensitization or desensitization can occur, where activation of one receptor system affects the responsiveness of another unrelated system.

Alterations in receptor regulation contribute to endocrine disorders and drug responses. For example, insulin resistance in type 2 diabetes is associated with reduced receptor signaling, while some hormone excess states involve receptor down-regulation or impaired signaling. Understanding receptor regulation is therefore essential for explaining both normal adaptation and pathological changes in endocrine function.

2.6 Endocrine–nervous–immune interactions

Endocrine, nervous, and immune systems communicate extensively to maintain homeostasis and coordinate responses to stress, infection, and injury. The hypothalamus and pituitary link neural activity with hormone secretion, while many hormones modulate neural and immune function.

The hypothalamic–pituitary–adrenal (HPA) axis is a classic example of integration. Psychological or physical stress activates hypothalamic neurons to release corticotropin-releasing hormone, which stimulates the pituitary to secrete adrenocorticotrophic hormone (ACTH). ACTH then drives cortisol secretion from the adrenal cortex. Cortisol, in turn, feeds back on the hypothalamus and pituitary and also modulates immune responses by suppressing inflammatory cytokines and cell activity. This system helps limit excessive inflammation during stress but can also contribute to immune suppression if chronically activated.

Many cytokines produced by immune cells act on the brain and endocrine glands. Interleukins and tumor necrosis factor can stimulate the HPA axis and alter thyroid and gonadal function. Conversely, hormones such as cortisol, sex steroids, and growth hormone influence the development, activation, and function of immune cells. These bidirectional interactions are important in conditions such as chronic stress, autoimmune diseases, and malnutrition.

Neuroendocrine cells and neurotransmitters also affect hormone secretion. For example, catecholamines from the sympathetic nervous system stimulate the adrenal medulla to release epinephrine and norepinephrine, while parasympathetic signals influence

pancreatic hormone secretion. Neuropeptides in the brain can regulate appetite, thirst, and reproductive behavior through hormonal pathways.

Recognizing that endocrine, nervous, and immune systems form a network rather than acting in isolation helps explain the complexity of physiological regulation and the multisystem nature of many endocrine and metabolic disorders. Endocrinology, therefore, cannot be fully understood without considering its crosstalk with other regulatory systems.

KEY CONCEPTS:

- ☑ **Peptide hormones:** Preprohormone → Prohormone → Granules → Exocytosis (stored)
- ☑ **Steroid hormones:** Cholesterol → Pregnenolone → Diffuse out (NOT stored)
- ☑ **Transport:** Peptides = free; Steroids/Thyroid = bound (CBG, SHBG, TBG)
- ☑ **Receptors:** Water-soluble = Cell surface; Lipid-soluble = Nuclear
- ☑ **Regulation:** Up-regulation (low hormone), Down-regulation (high hormone)

Clinical correlation 2.1 Steroid Withdrawal

A 45-year-old woman on prednisone 20mg daily for 6 months stops suddenly.

She develops nausea, low blood pressure (90/60), and fatigue.

Labs: Morning cortisol <1 µg/dL (very low), ACTH low.

Diagnosis: Secondary adrenal insufficiency (HPA axis suppression)

Treatment: Restart hydrocortisone, slow taper over 3 months

Clinical correlation 2.2 Insulin Resistance

50M diabetic, obese, blood sugar 250 mg/dL despite insulin.

Problem: Insulin receptors DOWN-REGULATED from chronic high insulin.

Solution: Weight loss + metformin → Receptor up-regulation

Chapter 3: Hypothalamus–Pituitary Axis and Control Systems

3.1 Anatomy of the hypothalamus and pituitary gland

The hypothalamus and pituitary gland together form the central command center of the endocrine system. The hypothalamus is a small region of the brain located below the thalamus and above the brainstem, while the pituitary gland lies in a bony cavity called the sella turcica, just below the hypothalamus and connected to it by the pituitary stalk (infundibulum).

The hypothalamus consists of several nuclei that have distinct endocrine and autonomic functions. Key nuclei include the paraventricular and supraoptic nuclei, which produce antidiuretic hormone (ADH, or vasopressin) and oxytocin. These hormones are transported along axons to the posterior pituitary, where they are stored and released. Other hypothalamic nuclei, such as the arcuate, ventromedial, and preoptic nuclei, secrete releasing and inhibiting hormones that regulate the anterior pituitary.

The pituitary gland, also called the hypophysis, is divided into two main parts: the anterior pituitary (adenohypophysis) and the posterior pituitary (neurohypophysis). The anterior pituitary develops from an upward invagination of the oral ectoderm (Rathke's pouch) and consists of glandular epithelial cells. The posterior pituitary develops from a downward extension of the neuroectoderm and is composed mainly of nerve endings and glial cells.

The anterior pituitary contains several types of cells that secrete specific hormones. These include somatotrophs (growth hormone), thyrotrophs (thyroid-stimulating hormone), corticotrophs (adrenocorticotrophic hormone), lactotrophs (prolactin), and gonadotrophs (follicle-stimulating hormone and luteinizing hormone). Blood supply to the anterior pituitary is provided by the hypothalamic–hypophyseal portal system, a network of capillaries that carries hypothalamic releasing and inhibiting hormones directly from the hypothalamus to the anterior pituitary without mixing with general circulation.

The posterior pituitary does not synthesize hormones but stores and releases hormones produced in the hypothalamus. Axons from the paraventricular and supraoptic nuclei descend through the pituitary stalk and terminate in the posterior pituitary. When these neurons are activated, they release ADH and oxytocin into the bloodstream.

The close anatomical and vascular connection between the hypothalamus and pituitary allows neural signals from the brain to regulate hormone secretion rapidly and precisely. This system integrates information about stress, light–dark cycles, temperature, blood osmolarity, and metabolic status, and translates them into coordinated endocrine responses. Understanding the basic anatomy of the hypothalamus and pituitary is essential for studying the control of major endocrine axes and for interpreting clinical disorders of the central endocrine system.

3.2 Hypothalamic–pituitary–thyroid axis

The hypothalamic–pituitary–thyroid (HPT) axis is a classic endocrine feedback system that regulates the production and secretion of thyroid hormones. It consists of the hypothalamus, the anterior pituitary, and the thyroid gland, linked by specific releasing hormones and trophic hormones.

The hypothalamus produces thyrotropin-releasing hormone (TRH) in neurons of the paraventricular nucleus. TRH is released into the hypothalamic–hypophyseal portal blood vessels and carried to the anterior pituitary. Here, it binds to receptors on thyrotroph cells and stimulates the synthesis and secretion of thyroid-stimulating hormone (TSH), also called thyrotropin.

TSH travels in the general circulation and acts on the thyroid gland, which is located in the neck and consists of many follicles filled with colloid. TSH binds to receptors on the basolateral membrane of thyroid follicular cells and activates signaling pathways that increase iodide uptake, thyroglobulin synthesis, and the production of thyroid hormones. The two main thyroid hormones are thyroxine (T_4) and triiodothyronine (T_3), which are stored in the follicular colloid bound to thyroglobulin and released into the blood when needed.

In the circulation, most T_4 and a smaller fraction of T_3 are bound to plasma proteins such as thyroxine-binding globulin (TBG), transthyretin, and albumin. Only the free, unbound hormone can enter target cells and exert biological effects. In tissues such as the liver,

kidney, and brain, T_4 is converted to the more active T_3 by deiodinase enzymes. T_3 then binds to nuclear thyroid hormone receptors, which regulate gene expression and influence metabolic rate, growth, development, and cardiovascular function.

The activity of the HPT axis is tightly controlled by negative feedback. When blood levels of T_4 and T_3 rise, they act on the pituitary and hypothalamus to suppress the secretion of TSH and TRH, respectively. This prevents overproduction of thyroid hormones. Conversely, low thyroid hormone levels reduce feedback inhibition, leading to increased TRH and TSH secretion and stimulation of the thyroid gland.

The HPT axis also responds to other factors. Stress, illness, and certain drugs can transiently alter TSH and thyroid hormone levels. Seasonal changes, nutritional status, and age influence the set point of the system. Dysregulation of the HPT axis leads to clinical disorders such as hypothyroidism, hyperthyroidism, and goiter, which are usually diagnosed by measuring TSH and free T_4 in the blood.

Understanding the HPT axis is central to endocrinology because it illustrates key principles of hormone regulation, feedback control, and the integration of neural and endocrine signals. It also provides a model for studying similar regulatory systems, such as the hypothalamic–pituitary–adrenal and hypothalamic–pituitary–gonadal axes.

3.3 Hypothalamic–pituitary–adrenal axis

The hypothalamic–pituitary–adrenal (HPA) axis is a major neuroendocrine system that regulates the body's response to stress and maintains homeostasis. It connects the hypothalamus, the anterior pituitary, and the adrenal cortex through a chain of releasing and trophic hormones.

The hypothalamus produces corticotropin-releasing hormone (CRH) in neurons of the paraventricular nucleus. CRH is released into the hypothalamic–hypophyseal portal vessels and carried to the anterior pituitary. There, it binds to receptors on corticotroph cells and stimulates the synthesis and secretion of adrenocorticotrophic hormone (ACTH), also known as corticotropin.

ACTH enters the general circulation and acts on the adrenal cortex, which is the outer part of the adrenal glands located on top of the kidneys. The adrenal cortex consists of three layers: the zona glomerulosa, zona fasciculata, and zona reticularis. ACTH primarily

targets the zona fasciculata and, to a lesser extent, the zona reticularis, stimulating the synthesis and release of glucocorticoids, mainly cortisol.

Cortisol is a steroid hormone that influences many tissues. It increases glucose production in the liver, promotes protein breakdown in muscle, and inhibits non-essential functions such as inflammation and immune responses. Cortisol also helps the body adapt to stress by maintaining blood pressure, enhancing vascular tone, and supporting energy availability. Its secretion follows a circadian rhythm, with higher levels in the early morning and lower levels at night.

The HPA axis is regulated by negative feedback. Rising cortisol levels act on the pituitary and hypothalamus to suppress the secretion of ACTH and CRH, preventing excessive cortisol production. When cortisol levels fall, feedback inhibition decreases, allowing CRH and ACTH secretion to increase and stimulate the adrenal cortex again.

In addition to cortisol, the adrenal cortex produces mineralocorticoids, mainly aldosterone, which are regulated primarily by the renin–angiotensin system and by potassium levels, and adrenal androgens, such as dehydroepiandrosterone (DHEA). These hormones influence salt and water balance, blood pressure, and aspects of sexual development.

The HPA axis also interacts with other systems. Stressors such as infection, injury, surgery, or psychological stress activate the hypothalamus and increase CRH and ACTH secretion, leading to higher cortisol levels. Chronic activation of the HPA axis can contribute to metabolic and immune changes, while under-activity can lead to adrenal insufficiency.

Disorders of the HPA axis include Cushing's syndrome (excess cortisol), Addison's disease (adrenal insufficiency), and secondary adrenal disorders due to pituitary or hypothalamic disease. These conditions are usually diagnosed by measuring cortisol, ACTH, and their responses to stimulation or suppression tests.

Understanding the HPA axis is important because it illustrates how the brain, pituitary, and adrenal glands work together to control stress responses and maintain metabolic and immune balance. It also provides a model for studying feedback regulation and the integration of endocrine, nervous, and immune functions.

3.4 Hypothalamic–pituitary–gonadal axis

The hypothalamic–pituitary–gonadal (HPG) axis regulates reproduction, sexual development, and secondary sexual characteristics. It involves the hypothalamus, the anterior pituitary, and the gonads (ovaries in females and testes in males).

The hypothalamus produces gonadotropin-releasing hormone (GnRH) in specialized neurons. GnRH is released in a pulsatile manner into the hypothalamic–hypophyseal portal blood and carried to the anterior pituitary. There, it acts on gonadotroph cells, stimulating the synthesis and secretion of two gonadotropins: follicle-stimulating hormone (FSH) and luteinizing hormone (LH).

FSH and LH travel in the circulation and act on the gonads. In the testes, FSH acts on Sertoli cells to support spermatogenesis, while LH acts on Leydig cells to stimulate the production of testosterone and other androgens. Testosterone promotes male sexual development, secondary sexual characteristics, and spermatogenesis. It also exerts negative feedback on the hypothalamus and pituitary to regulate GnRH, FSH, and LH secretion.

In the ovaries, FSH stimulates the growth and maturation of ovarian follicles and the production of estrogens, mainly estradiol. Estradiol influences the development of female reproductive organs, the menstrual cycle, and secondary sexual characteristics. LH triggers ovulation and stimulates the formation of the corpus luteum, which produces progesterone and additional estrogen. Progesterone prepares the endometrium for implantation and maintains early pregnancy.

The activity of the HPG axis is regulated by multiple feedback mechanisms. Rising estradiol and progesterone from the ovaries inhibit GnRH, FSH, and LH secretion during most of the menstrual cycle. However, at mid-cycle, a high and sustained estradiol level can produce a positive feedback effect, leading to a surge in LH that triggers ovulation. After ovulation, the corpus luteum produces hormones that maintain the endometrium; if pregnancy does not occur, the corpus luteum regresses, hormone levels fall, and menstruation begins.

In males, testosterone and inhibin from the testes provide continuous negative feedback on the hypothalamus and pituitary, keeping gonadotropin secretion within a stable range.

Puberty begins when the hypothalamus increases GnRH pulsatility, leading to activation of the HPG axis and the development of secondary sexual characteristics.

Disorders of the HPG axis include hypogonadism, infertility, precocious or delayed puberty, and conditions such as polycystic ovary syndrome (PCOS). These are usually evaluated by measuring FSH, LH, and sex steroids and interpreting their patterns in relation to age and sex.

Understanding the HPG axis is essential for studying reproductive endocrinology, fertility, and disorders of sexual development. It also illustrates how feedback, pulsatility, and sexual differentiation shape endocrine function across the lifespan.

Table 3.1: Main hypothalamic–pituitary axes and their hormones

Axis (abbreviation)	Hypothalamic hormone	Pituitary hormone	Target gland	Main regulated hormones
HPT	TRH	TSH	Thyroid	T ₄ , T ₃
HPA	CRH, AVP	ACTH	Adrenal cortex	Cortisol, androgens
HPG (male)	GnRH	FSH, LH	Testes	Testosterone, spermatogenesis
HPG (female)	GnRH	FSH, LH	Ovaries	Estradiol, progesterone
Somatotropic	GHRH, somatostatin	GH	Liver, tissues	IGF-1, growth
Prolactin axis	Dopamine (inhibitory)	Prolactin	Mammary gland	Milk synthesis

3.5 Somatotrophic axis: growth hormone and IGF-1

The somatotrophic axis, or growth-hormone axis, regulates growth, body composition, and metabolic processes. It involves the hypothalamus, the anterior pituitary, and target tissues, including the liver, which produces insulin-like growth factor-1 (IGF-1).

The hypothalamus produces growth hormone–releasing hormone (GHRH) and somatostatin (growth hormone–inhibiting hormone, GHIH). GHRH stimulates the release of growth hormone (GH) from somatotroph cells in the anterior pituitary, while somatostatin inhibits GH secretion. The balance between these two hypothalamic hormones, along with feedback from GH and IGF-1, determines the pattern of GH release.

GH is secreted in a pulsatile manner, with a major surge occurring during deep sleep. In children and adolescents, GH promotes longitudinal growth by stimulating the epiphyseal plates of long bones. It also increases muscle mass, reduces adipose tissue, and influences protein, carbohydrate, and lipid metabolism. In adults, GH continues to affect body composition and metabolism, though its role in linear growth has ended.

GH acts directly on some tissues, but many of its growth-promoting effects are mediated by IGF-1, a peptide hormone produced mainly by the liver in response to GH stimulation. IGF-1 circulates in the blood, bound to specific binding proteins, and acts on various tissues to promote cell proliferation, differentiation, and survival. It also exerts negative feedback on the hypothalamus and pituitary, reducing GHRH and GH secretion.

The somatotrophic axis is influenced by nutrition, sleep, exercise, and stress. Fasting or low protein intake can suppress GH secretion, while adequate nutrition and deep sleep enhance it. Hormones such as insulin, sex steroids, and thyroid hormones also modulate GH and IGF-1 activity.

Disorders of the somatotrophic axis include growth hormone deficiency, which may cause short stature in children, and growth hormone excess, which leads to gigantism in children or acromegaly in adults. Excess GH can also contribute to metabolic disturbances such as insulin resistance. Diagnosis usually involves measuring GH and IGF-1 levels and performing stimulation or suppression tests.

Understanding the GH–IGF-1 axis is important for studying growth, metabolism, and aging. It also provides insights into the use of GH and IGF-1 in clinical and experimental settings.

3.6 Prolactin and its regulation

Prolactin is a peptide hormone produced by lactotroph cells in the anterior pituitary. It plays a central role in mammary gland development and milk production, but it also has other physiological and reproductive functions.

Prolactin secretion is primarily under tonic inhibitory control by dopamine from the hypothalamus. Dopamine, also called prolactin-inhibiting factor, binds to receptors on lactotrophs and suppresses prolactin release. When dopamine levels decrease, prolactin secretion increases. Other factors that stimulate prolactin release include thyrotropin-releasing hormone (TRH), estrogens, suckling and stress.

During pregnancy, rising estrogen levels increase the number and size of lactotrophs and enhance prolactin synthesis. Prolactin promotes the growth and development of the mammary glands and prepares them for lactation. After delivery, suckling stimulates neural signals that inhibit dopamine release, leading to increased prolactin and milk production.

Prolactin also affects the reproductive system. In females, high prolactin levels can inhibit GnRH secretion, leading to reduced FSH and LH release, anovulation, and amenorrhea. In males, hyperprolactinemia can reduce testosterone production and cause infertility and sexual dysfunction.

Disorders of prolactin secretion include hyperprolactinemia, often due to pituitary tumors (prolactinomas), medications, or hypothalamic lesions that reduce dopamine. Hyperprolactinemia is less common but can impair lactation. Diagnosis involves measuring serum prolactin levels and, if necessary, imaging studies of the pituitary.

Understanding prolactin regulation highlights the importance of dopamine in pituitary control and illustrates how a single hormone can influence both lactation and reproductive function.

3.7 Posterior pituitary hormones: vasopressin and oxytocin

The posterior pituitary stores and releases two important peptide hormones: vasopressin (antidiuretic hormone, ADH) and oxytocin. These hormones are synthesized in the hypothalamus and transported to the posterior pituitary via axons.

Vasopressin normally released in response to increased plasma osmolarity or decreased blood volume, vasopressin acts on the kidneys to increase water reabsorption and reduce urine output. It also causes vasoconstriction, which helps maintain blood pressure. Dysregulation of vasopressin leads to disorders such as diabetes insipidus (excessive urine output due to lack of vasopressin or kidney resistance) and syndrome of inappropriate antidiuretic hormone secretion (SIADH), where excess vasopressin causes water retention and hyponatremia.

Oxytocin is released in response to suckling, during childbirth, and in response to certain emotional and sensory stimuli. It stimulates contraction of myoepithelial cells in the mammary glands, facilitating milk ejection, and promotes uterine contractions during labor. Oxytocin also plays a role in social bonding, maternal behavior, and stress regulation, though these effects are complex and still being studied. Both vasopressin and oxytocin are small peptides with similar structures but distinct receptors and actions. Their secretion is regulated by neural inputs from the hypothalamus and by feedback mechanisms related to fluid balance, blood pressure, and reproductive status.

TABLE 3.2: Posterior Pituitary Hormones

Hormone	Hypothalamic Origin	Stimulus	Target	Function
ADH (Vasopressin)	Supraoptic/Paraventricular	↑Osmolarity, ↓Volume	Kidney (V2), Vessels (V1)	Water retention, ↑BP
Oxytocin	Paraventricular	Suckling, Labor	Uterus, Breast	Contraction, Milk let-down

3.8 Disorders of the hypothalamus–pituitary complex

The hypothalamus–pituitary complex is vulnerable to various disorders that can disrupt multiple endocrine axes. These disorders may arise from structural lesions, inflammatory or autoimmune processes, vascular events, tumors, or genetic defects.

Pituitary tumors are among the most common causes of hypothalamic–pituitary dysfunction. They may secrete excess hormones, such as prolactin (prolactinomas), growth hormone (causing acromegaly or gigantism), or ACTH (causing Cushing's disease). Non-functioning tumors compress normal pituitary tissue, leading to hypopituitarism, a deficiency of one or more pituitary hormones.

Hypothalamic lesions due to trauma, tumors, radiation, or inflammatory diseases can impair the release of hypothalamic hormones, resulting in secondary hypopituitarism. Conversely, hypothalamic tumors may secrete excessive releasing hormones, leading to hormone overproduction.

Other disorders include diabetes insipidus, due to deficient vasopressin production or action, and syndrome of inappropriate antidiuretic hormone secretion (SIADH), characterized by excessive vasopressin activity. Craniopharyngiomas and other sellar masses can compress the optic chiasm and pituitary stalk, causing visual disturbances and hormonal deficiencies.

Diagnosis of hypothalamic–pituitary disorders involves detailed history, examination, imaging (usually MRI), and dynamic endocrine testing to assess hormone reserves and feedback responses. Treatment may include hormone replacement, surgery, radiation, or medical therapy to control hormone excess.

Understanding the hypothalamus–pituitary complex and its disorders is crucial for diagnosing and managing a wide range of endocrine conditions. It also emphasizes the importance of integrating clinical, biochemical, and radiological findings in endocrine practice.

TABLE 3.3: Common Pituitary Disorders

Disorder	Hormone Affected	Symptoms	Diagnosis	Treatment
Prolactinoma	↑Prolactin	Amenorrhea, Galactorrhea	Prolactin >200 ng/mL, MRI	Cabergoline
Acromegaly	↑GH/IGF-1	Large hands/feet, Jaw	IGF-1 ↑, OGTT GH no suppress	Surgery
Addison's (Secondary)	↓ACTH/Cortisol	Fatigue, Hypotension	Morning cortisol <5 µg/dL	Hydrocortisone
Diabetes Insipidus	↓ADH	Polyuria (>3L/day)	Water deprivation test	Desmopressin

KEY CONCEPTS:

- ☒ **Hypothalamus:** Produces releasing/inhibiting hormones → Portal system → Anterior pituitary
- ☒ **Anterior Pituitary:** TSH, ACTH, FSH/LH, GH, Prolactin (glandular)
- ☒ **Posterior Pituitary:** ADH (water), Oxytocin (milk/uterus) - stores hypothalamic hormones
- ☒ **4 Major Axes:** HPT (thyroid), HPA (stress), HPG (reproduction), Somatotropic (growth)
- ☒ **Prolactin:** Dopamine inhibits (main control)

Clinical Correlation 3.1: Prolactinoma

28F: No periods 6 months, milky breast discharge.

No pregnancy. Headache, normal vision.

Labs: Prolactin 350 ng/mL ↑↑ (N: <25), TSH normal.

MRI: 1cm pituitary microadenoma.

Diagnosis: Prolactinoma

Treatment: Cabergoline 0.5mg twice weekly

Clinical Correlation 3.2: Central Hypothyroidism

40M: Fatigue, cold intolerance post-head injury.

Labs: TSH normal (2.0), FT4 low (0.5 ng/dL).

TRH test: No TSH rise. MRI: Pituitary stalk damage.

Diagnosis: Secondary hypothyroidism

Treatment: Levothyroxine 75µg daily

Chapter 4: Thyroid and Parathyroid

Physiology and Pathology

4.1 Thyroid gland structure and iodine metabolism

The thyroid gland is a butterfly-shaped endocrine organ located in the anterior neck, just below the larynx. It consists of two lateral lobes connected by a narrow isthmus and, in some individuals, an additional pyramidal lobe. The gland is covered by a connective-tissue capsule and is highly vascularized, reflecting its role in hormone synthesis and secretion.

Microscopically, the thyroid is composed of thyroid follicles, which are spherical units formed by a single layer of follicular cells surrounding a central lumen filled with a protein-rich substance called colloid. The colloid contains thyroglobulin, a large glycoprotein that serves as the scaffold for thyroid hormone synthesis. Between the follicles are parafollicular cells (C cells), which produce calcitonin but are not involved in the classical thyroid hormone synthesis pathway.

Thyroid hormone synthesis requires iodine, an essential trace element obtained from the diet, mainly from iodized salt, seafood, and some dairy products. Iodine is absorbed in the gastrointestinal tract and transported in the blood as iodide. Thyroid follicular cells actively take up iodide from the circulation through a transmembrane protein called the sodium–iodide symporter (NIS), which concentrates iodide against its gradient using the energy of the sodium gradient.

Once inside the follicular cell, iodide is transported to the apical membrane and oxidized to iodine by the enzyme thyroid peroxidase (TPO). This reaction occurs in the presence of hydrogen peroxide, which is generated by dedicated enzymes at the apical membrane. The oxidized iodine then attaches to tyrosine residues within thyroglobulin, a process called iodination.

Monoiodotyrosine (MIT) and diiodotyrosine (DIT) are formed as intermediates. When two iodinated tyrosines are coupled together, thyroxine (T_4) and triiodothyronine (T_3) are produced within the thyroglobulin molecule. T_4 contains four iodine atoms, while T_3

contains three. Most of the hormone stored in the colloid is T_4 , with a smaller amount of T_3 .

When thyroid-stimulating hormone (TSH) from the anterior pituitary acts on the thyroid, it stimulates the uptake of iodide, the synthesis of thyroglobulin, and the endocytosis of colloid into follicular cells. The endocytosed colloid is fused with lysosomes, where proteolytic enzymes digest thyroglobulin, releasing T_4 and T_3 into the circulation. Some MIT and DIT are deiodinated and the iodide is recycled for further hormone synthesis.

Regulation of iodine uptake and hormone synthesis involves TSH, iodine availability, and feedback from circulating T_4 and T_3 . Low iodine intake can lead to reduced hormone production, enlargement of the thyroid (goiter), and hypothyroidism, whereas excessive iodine can transiently inhibit hormone release (Wolff–Chaikoff effect). Understanding thyroid structure and iodine metabolism is essential for interpreting thyroid disorders and the effects of dietary and therapeutic iodine.

4.2 Synthesis, secretion, and transport of thyroid hormones

Thyroid hormone synthesis begins in the follicular cells of the thyroid gland and proceeds through several biochemical steps. The key hormones are thyroxine (T_4) and triiodothyronine (T_3), which differ in the number of iodine atoms and metabolic activity.

As described earlier, iodide is taken up by follicular cells through the sodium–iodide symporter and oxidized to iodine by thyroid peroxidase. Iodine is then attached to tyrosine residues in thyroglobulin to form monoiodotyrosine (MIT) and diiodotyrosine (DIT). Coupling of MIT and DIT produces T_4 and T_3 within the thyroglobulin molecule stored in the follicular colloid. TSH stimulates the synthesis of thyroglobulin, iodination, and the endocytosis of colloid for hormone release.

Once released from thyroglobulin, T_4 and T_3 enter the bloodstream. In the circulation, the majority of thyroid hormones are bound to plasma proteins, mainly thyroxine-binding globulin (TBG), with smaller fractions bound to transthyretin and albumin. Only a small percentage of T_4 and T_3 circulates in the free form, but it is the free hormone that can diffuse into target cells and exert biological effects. Binding proteins serve as a reservoir, prolong hormone half-life, and buffer against rapid changes in hormone concentration.

In peripheral tissues such as the liver, kidney, and brain, deiodinase enzymes convert T_4 into the more biologically active T_3 by removing one iodine atom. Some T_4 is also converted to reverse T_3 (rT_3), an inactive form. The relative activity of these deiodinases determines the availability of active thyroid hormone at the tissue level. Factors such as illness, fasting, and certain drugs can alter deiodinase activity and affect thyroid hormone action.

Thyroid hormone secretion is regulated by the hypothalamic–pituitary–thyroid (HPT) axis. The hypothalamus releases thyrotropin-releasing hormone (TRH), which stimulates the anterior pituitary to secrete TSH. TSH, in turn, promotes thyroid hormone synthesis and release. Rising levels of T_4 and T_3 exert negative feedback on the pituitary and hypothalamus, reducing TRH and TSH secretion and maintaining hormone levels within a narrow range.

Thyroid hormones are lipophilic and enter cells by passive diffusion or specific transporters. Inside the cell, T_3 binds to nuclear thyroid hormone receptors, which act as transcription factors and regulate the expression of genes involved in metabolism, growth, development, and thermogenesis. The response to thyroid hormones is therefore relatively slow but long-lasting, affecting multiple organ systems.

Disorders of thyroid hormone synthesis or secretion, such as congenital hypothyroidism, Hashimoto's thyroiditis, or Graves' disease, reflect disturbances in these processes. Understanding the synthesis, secretion, and transport of thyroid hormones provides the basis for interpreting thyroid function tests and designing appropriate treatment strategies.

4.3 Mechanisms of thyroid hormone action

Thyroid hormones exert their effects primarily by binding to nuclear receptors and regulating gene expression, although non-genomic actions also occur at the cell membrane and in the cytoplasm.

Thyroid hormones enter target cells by diffusion or specific membrane transporters. In the cytoplasm, most T_4 is converted to the more active T_3 by deiodinase enzymes. T_3 has a much higher affinity for thyroid hormone receptors than T_4 . The receptors are nuclear

proteins belonging to the nuclear receptor superfamily and are present in many tissues, including the liver, heart, skeletal muscle, brain, and bone.

In the nucleus, thyroid hormone receptors bind to specific DNA sequences called thyroid hormone response elements (TREs) located in the regulatory regions of target genes. In the absence of hormone, the receptors may be associated with corepressor proteins that suppress gene transcription. When T_3 binds, a conformational change occurs, leading to the release of corepressors and recruitment of coactivators, which stimulate transcription of target genes.

Thyroid hormones increase the expression of genes involved in basal metabolic rate, oxygen consumption, and heat production. They enhance the activity of sodium–potassium ATPase and other ion transport systems, increase the number and efficiency of mitochondria, and stimulate glucose and fatty acid oxidation. These actions raise energy expenditure and contribute to the thermogenic effect of thyroid hormones.

In the cardiovascular system, thyroid hormones increase heart rate, contractility, and cardiac output by modulating the expression of ion channels and contractile proteins. In the central nervous system, they are essential for normal brain development and function, particularly during fetal and early postnatal life. Deficiency of thyroid hormones during this period can lead to irreversible intellectual disability and growth retardation.

Thyroid hormones also influence growth and development by interacting with the growth hormone–IGF-1 axis and by modulating the effects of other hormones. In bone, they promote maturation and turnover, while in reproductive tissues they affect the menstrual cycle and fertility.

Non-genomic actions of thyroid hormones occur more rapidly and do not require gene transcription. These include effects on membrane ion channels, intracellular calcium levels, and activation of kinases. Such actions may complement the slower genomic effects and contribute to the overall physiological response.

Understanding the mechanisms of thyroid hormone action explains why hypothyroidism and hyperthyroidism produce widespread effects on metabolism, cardiovascular function, neuropsychological state, and growth. It also provides a framework for using thyroid hormone analogs and receptor modulators in clinical practice.

4.4 Regulation of thyroid function and diagnostic tests

Thyroid function is tightly regulated by the hypothalamic–pituitary–thyroid (HPT) axis and by local factors within the thyroid gland. The main regulators are thyrotropin-releasing hormone (TRH), thyroid-stimulating hormone (TSH), and circulating thyroid hormones, along with iodine availability and autoregulatory mechanisms.

The hypothalamus secretes TRH, which stimulates the anterior pituitary to release TSH. TSH then acts on the thyroid gland to increase iodide uptake, thyroglobulin synthesis, hormone iodination, and hormone release. As blood levels of T_4 and T_3 rise, they exert negative feedback on the pituitary and hypothalamus, reducing TRH and TSH secretion. This feedback loop maintains thyroid hormone levels within a normal range.

In addition to systemic regulation, the thyroid gland can respond to changes in iodine supply. Mild iodine deficiency stimulates TSH secretion and thyroid growth, leading to goiter as an adaptive response. Excessive iodine intake can temporarily inhibit hormone release through the Wolff–Chaikoff effect, although this inhibition is usually transient due to an escape mechanism that restores normal hormone production.

Local factors such as cytokines, growth factors, and autoantibodies can also influence thyroid function. Autoimmune thyroid diseases involve antibodies that either stimulate or damage the thyroid gland, leading to hyperthyroidism or hypothyroidism, respectively.

Clinical evaluation of thyroid function relies on several laboratory tests. Serum TSH is the most sensitive indicator of thyroid status and is usually the first test ordered. In primary hypothyroidism, TSH is elevated and free T_4 is low; in primary hyperthyroidism, TSH is suppressed and free T_4 (and often free T_3) is high. Free T_4 and free T_3 measurements reflect the biologically active hormone fraction and help distinguish primary from central (pituitary or hypothalamic) thyroid disorders.

Additional tests include thyroid peroxidase antibodies (TPOAb) and thyroglobulin antibodies (TgAb), which are often elevated in autoimmune thyroid diseases such as Hashimoto's thyroiditis and Graves' disease. Radioactive iodine uptake and thyroid scintigraphy may be used to assess gland activity and to differentiate causes of hyperthyroidism. Ultrasound of the thyroid provides information about gland size, structure, and the presence of nodules.

Dynamic tests, such as the TRH stimulation test, are rarely used but can help evaluate central hypothyroidism or pituitary dysfunction. Interpretation of thyroid function tests must consider the clinical context, including symptoms, age, medications, and non-thyroidal illness.

Understanding the regulation of thyroid function and the use of diagnostic tests is essential for diagnosing and managing thyroid disorders. It also illustrates the integration of biochemical, immunological, and imaging approaches in endocrine practice.

Table 4.1: Main thyroid function tests and their interpretation

Test	Pattern in primary hypothyroidism	Pattern in primary hyperthyroidism	Comment
TSH	High	Low	First-line test
Free T ₄	Low	High	Best measure of active hormone
Free T ₃	Low/near-normal	High	Often elevated in hyperthyroidism
TPO antibodies	Usually positive	May be positive in Graves'	Supports autoimmune disease

4.5 Goiter, thyroid nodules, and cancer

Goiter refers to an enlarged thyroid gland, which may be diffuse or nodular. It is often a visible or palpable mass in the neck and can cause cosmetic concerns or compressive symptoms such as difficulty swallowing, breathing, or speaking. Goiter may occur with normal, increased, or decreased thyroid function.

The most common cause of goiter worldwide is iodine deficiency, which reduces thyroid hormone synthesis and triggers compensatory TSH-stimulated growth of the gland. Other causes include autoimmune thyroid diseases, such as Hashimoto's thyroiditis and Graves'

disease, and genetic or environmental factors that affect thyroid hormone synthesis or regulation.

Thyroid nodules are focal lesions within the thyroid gland that may be benign or malignant. Most nodules are discovered incidentally on imaging studies or during physical examination. Evaluation includes assessment of symptoms, family history, radiation exposure, and thyroid function tests. Ultrasound is the primary imaging modality, which can characterize nodule size, composition, and suspicious features such as microcalcifications, irregular margins, or increased vascularity.

Fine-needle aspiration (FNA) biopsy is used to obtain cells from suspicious nodules for cytological examination. This helps distinguish benign nodules from those that may be malignant, such as papillary, follicular, medullary, or anaplastic thyroid carcinomas. Most thyroid cancers are differentiated carcinomas (papillary and follicular) and have a relatively good prognosis with appropriate treatment.

Management of goiter and nodules depends on thyroid function, symptoms, and the risk of malignancy. Treatment options include thyroid hormone suppression, iodine supplementation (in iodine-deficient regions), radioactive iodine ablation, or surgery. Benign nodules that are small and asymptomatic may be monitored with periodic ultrasound and clinical examination.

Understanding the causes and evaluation of goiter and thyroid nodules is important for early detection of thyroid cancer and for preventing complications such as airway compression or cosmetic disfigurement. It also highlights the role of preventive strategies, such as iodine fortification, in public health.

4.6 Autoimmune thyroid diseases: Graves' and Hashimoto's

Autoimmune thyroid diseases are disorders in which the immune system mistakenly attacks the thyroid gland. The two main forms are Graves' disease, characterized by hyperthyroidism, and Hashimoto's thyroiditis, characterized by hypothyroidism. Both are more common in women and often occur in individuals with other autoimmune conditions.

Graves' disease is caused by stimulating autoantibodies directed against the thyrotropin receptor (TSHR). These TSH receptor antibodies (TRAb) mimic the action of TSH,

continuously activating the receptor and leading to excessive production and secretion of thyroid hormones. This results in hyperthyroidism with symptoms such as weight loss, heat intolerance, palpitations, tremors, anxiety, and exophthalmos (protrusion of the eyes).

Graves' disease may also involve the orbital tissues, leading to thyroid eye disease, with swelling, redness, and double vision. The diagnosis is based on clinical features, elevated free T₄ and/or free T₃, suppressed TSH, and the presence of TRAb. Radioactive iodine uptake is typically diffusely increased.

Treatment options include antithyroid drugs (e.g., methimazole or propylthiouracil), which inhibit thyroid peroxidase and reduce hormone synthesis; radioactive iodine therapy, which destroys thyroid tissue; and thyroidectomy, the surgical removal of the thyroid gland. Beta-blockers may be used to control symptoms while definitive treatment is initiated.

Hashimoto's thyroiditis is characterized by lymphocytic infiltration of the thyroid gland and progressive destruction of thyroid follicles. It leads to hypothyroidism, with symptoms such as fatigue, weight gain, cold intolerance, constipation, dry skin, and depression. The thyroid gland may be enlarged and firm (goiter) or, in advanced stages, atrophic.

Laboratory findings include elevated TSH, low free T₄, and positive antithyroid antibodies, particularly thyroid peroxidase antibodies (TPOAb) and thyroglobulin antibodies (TgAb). The diagnosis is usually clinical and serological; imaging or biopsy is rarely needed unless there are suspicious nodules.

Treatment of Hashimoto's thyroiditis involves levothyroxine replacement therapy, which restores euthyroidism and reverses most symptoms. Regular monitoring of TSH and, in some cases, free T₄, is necessary to adjust the dose.

Understanding autoimmune thyroid diseases illustrates the interaction between the immune and endocrine systems and the importance of autoantibodies in diagnosis and pathogenesis. It also highlights the need for lifelong follow-up in many patients to maintain optimal hormone replacement.

Table 4.2: Main differences between Graves' disease and Hashimoto's thyroiditis

Feature	Graves' disease	Hashimoto's thyroiditis
Typical thyroid function	Hyperthyroidism	Hypothyroidism
Main hormone level	High T ₄ /T ₃ , low TSH	Low T ₄ , high TSH
Autoantibodies	TSH-receptor stimulating antibodies (TRAb)	TPO and/or Tg antibodies
Eye changes	Exophthalmos common	Not typical
Goiter type	Diffuse, vascular	Firm, irregular, or atrophic

Chapter 5: Adrenal Glands and Stress Physiology

5.1 Anatomy of adrenal cortex and medulla

The adrenal glands are paired endocrine organs located on top of the kidneys. Each gland has two functionally distinct parts: the adrenal cortex on the outside and the adrenal medulla in the center. The whole gland is surrounded by a connective-tissue capsule and receives a rich blood supply from branches of the abdominal aorta, renal arteries, and phrenic arteries.

TABLE 5.1: Adrenal Cortex Zones

Zone	Regulated By	Main Hormone	Function	Pathology
Glomerulosa (Outer)	Angiotensin II, K ⁺	Aldosterone	Na ⁺ retention, ↑BP	Conn's (↑Aldo)
Fasciculata (Middle)	ACTH	Cortisol (90%)	Stress response, ↑Glucose	Cushing's (↑Cortisol)
Reticularis (Inner)	ACTH	DHEA/Androgens	Puberty, sex drive	↑Hirsutism

The adrenal cortex is derived from mesoderm and consists of three histological zones arranged from outside to inside:

Zona glomerulosa (outer layer)

Zona fasciculata (middle layer)

Zona reticularis (inner layer)

The zona glomerulosa lies just beneath the capsule and is composed of small, closely packed cells arranged in rounded clusters. It is the main site of aldosterone production. The zona fasciculata forms the thickest part of the cortex and contains large, lipid-rich cells arranged in cords or columns. This zone produces glucocorticoids, mainly cortisol. The zona reticularis, adjacent to the medulla, consists of smaller, irregularly arranged cells and produces adrenal androgens, such as dehydroepiandrosterone (DHEA) and its sulfate (DHEA-S).

The adrenal medulla is derived from neural crest cells and is essentially a modified sympathetic ganglion. It contains chromaffin cells that synthesize and store the catecholamines epinephrine (adrenaline) and norepinephrine (noradrenaline). These cells receive direct sympathetic nerve fibers; when activated, they release catecholamines into the bloodstream. The medulla thus functions as part of the sympathetic nervous system and is closely linked to the body's "fight-or-flight" responses.

Blood flow in the adrenal gland is organized so that cortical blood vessels run through the cortex, and some of this blood reaches the medulla before draining into the systemic circulation. This arrangement allows some cortisol produced by the cortex to reach the medulla and influence catecholamine synthesis. Venous blood from the adrenal gland drains into the inferior vena cava (right side) and the renal vein (left side).

Understanding the basic anatomy of the adrenal cortex and medulla is essential because each zone produces different hormones that regulate metabolism, electrolyte balance, and stress responses. The structural difference between the cortex and medulla also reflects their different embryological origins and functional roles.

Table 5.2: Main adrenal hormones and their principal actions

Adrenal region	Main hormone(s)	Primary actions
Zona glomerulosa	Aldosterone	Sodium retention, potassium excretion, blood pressure

Adrenal region	Main hormone(s)	Primary actions
Zona fasciculata	Cortisol	Gluconeogenesis, anti-inflammatory, stress response
Zona reticularis	DHEA, DHEA-S	Precursors to sex steroids, androgenic effects
Adrenal medulla	Epinephrine, norepinephrine	“Fight-or-flight”: ↑ HR, BP, glucose, lipolysis

5.2 Glucocorticoids: synthesis, secretion, and actions

Glucocorticoids are steroid hormones produced mainly by the zona fasciculata of the adrenal cortex. The primary glucocorticoid in humans is cortisol, which plays a central role in metabolism, immunity, and adaptation to stress.

Cortisol is synthesized from cholesterol through a series of enzymatic reactions occurring in the mitochondria and endoplasmic reticulum. The rate-limiting step is the conversion of cholesterol to pregnenolone by the enzyme cholesterol side-chain cleavage enzyme (P450_{scc}). Subsequent reactions involving enzymes such as 17- α -hydroxylase, 21-hydroxylase, and 11 β -hydroxylase lead to the formation of cortisol.

Cortisol secretion is controlled by the hypothalamic–pituitary–adrenal (HPA) axis. The hypothalamus releases corticotropin-releasing hormone (CRH), which stimulates the anterior pituitary to secrete adrenocorticotrophic hormone (ACTH). ACTH then acts on the adrenal cortex to increase cholesterol uptake, steroidogenesis, and cortisol release. Cortisol exerts negative feedback on the hypothalamus and pituitary, inhibiting further secretion of CRH and ACTH.

Cortisol has widespread actions on many tissues. In the liver, it stimulates gluconeogenesis, the production of glucose from amino acids and other precursors, and increases the availability of glucose for vital organs. In muscle and adipose tissue, cortisol promotes protein breakdown and lipolysis, supplying amino acids and fatty acids as

alternative fuels. These effects help maintain blood glucose and energy supply during fasting or stress.

Cortisol also modulates immune and inflammatory responses. It suppresses the activity of several immune cells and reduces the production of inflammatory cytokines and mediators. This anti-inflammatory effect is useful in treating autoimmune and allergic diseases but can also increase susceptibility to infection if prolonged. Cortisol influences the cardiovascular system by enhancing vascular sensitivity to catecholamines, helping to maintain blood pressure.

Another important action of cortisol is its effect on the central nervous system, where it can influence mood, cognition, and arousal. Chronic excess cortisol may contribute to anxiety, depression, and impaired memory, whereas cortisol deficiency can cause fatigue and poor stress tolerance.

Cortisol secretion follows a circadian rhythm, with highest levels in the early morning and lowest levels at night. This rhythm is regulated by the central circadian clock in the hypothalamus and can be altered by shift work, sleep loss, or illness. Stress of any kind—physical, psychological, or metabolic—can also increase cortisol secretion.

Understanding the synthesis, regulation, and actions of glucocorticoids is essential for studying stress physiology, metabolic diseases, and autoimmune disorders. It also explains the widespread use of synthetic glucocorticoids (such as prednisone and dexamethasone) in clinical medicine.

5.3 Mineralocorticoids and sodium–potassium balance

Mineralocorticoids are steroid hormones that regulate electrolyte and water balance, mainly by acting on the kidneys. The primary mineralocorticoid is aldosterone, which is produced by the zona glomerulosa of the adrenal cortex.

Aldosterone synthesis is stimulated mainly by the renin–angiotensin system and by serum potassium levels. When blood pressure falls or renal blood flow decreases, the kidneys release renin, which converts angiotensinogen (produced by the liver) to angiotensin I. Angiotensin-converting enzyme (ACE) then converts angiotensin I to angiotensin II, which directly stimulates the adrenal cortex to secrete aldosterone. In addition, high

serum potassium levels activate aldosterone release, whereas low potassium suppresses it.

Aldosterone acts on the principal cells of the distal tubules and collecting ducts of the kidney. There, it binds to intracellular mineralocorticoid receptors and increases the expression of sodium channels (ENaC) and $\text{Na}^+\text{--K}^+$ ATPase pumps. This leads to increased reabsorption of sodium ions (Na^+) from the tubular fluid into the blood. As sodium is reabsorbed, water follows passively, so aldosterone also contributes to fluid retention and maintenance of blood volume and blood pressure.


At the same time, the increased sodium reabsorption generates a more negative electrical gradient in the tubular lumen, which promotes the secretion of potassium ions (K^+) into the urine. Aldosterone thus tends to increase serum sodium and decrease serum potassium. It also enhances hydrogen ion (H^+) secretion in some segments, helping to regulate acid–base balance.

Aldosterone secretion is modulated by several factors. Angiotensin II, potassium, and adrenocorticotrophic hormone (ACTH) all stimulate aldosterone release, whereas atrial natriuretic peptide (ANP) opposes its effects by promoting sodium and water excretion. Negative feedback mechanisms involving blood pressure, volume status, and potassium levels help maintain mineralocorticoid balance.

Disorders of mineralocorticoid function include primary hyperaldosteronism (Conn's syndrome), usually caused by an aldosterone-producing adrenal tumor or hyperplasia, and secondary hyperaldosteronism, which results from activation of the renin–angiotensin system in conditions such as heart failure or renal artery stenosis. Both forms lead to hypertension and hypokalemia. In contrast, aldosterone deficiency (as in Addison's disease or certain forms of congenital adrenal hyperplasia) causes sodium loss, volume depletion, hypotension, and hyperkalemia.

Understanding aldosterone and mineralocorticoid action is essential for interpreting electrolyte disturbances, hypertension, and renal–endocrine interactions. It also explains the pharmacological use of aldosterone antagonists (e.g., spironolactone, eplerenone) and other drugs that target the renin–angiotensin–aldosterone system.

Fig 7.2: HPA Axis and Cortisol Regulation (Stress Response)



5.4 Adrenal androgens

The adrenal cortex also produces androgen precursors, mainly in the zona reticularis. The most important adrenal androgens are dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEA-S), along with smaller amounts of androstenedione.

These hormones are weak androgens in themselves but can be converted in peripheral tissues (such as the skin, hair follicles, and gonads) into more potent androgens like testosterone and dihydrotestosterone (DHT). Adrenal androgens contribute to the development of pubic and axillary hair, sebaceous gland activity, and other androgen-dependent traits, particularly in females, whose gonadal androgen production is relatively low compared with males.

Normal adrenal androgen secretion increases at puberty and then gradually declines with age. DHEA-S is often used as a marker of adrenal androgen production because its circulating levels are relatively stable compared with the more rapidly fluctuating DHEA and androstenedione.

Excessive adrenal androgen production can occur in conditions such as congenital adrenal hyperplasia (CAH), adrenal tumors, or Cushing's syndrome. In females, this may lead to

hirsutism (excessive male-pattern hair growth), acne, menstrual irregularities, and, in some cases, masculinization. In males, excess adrenal androgens are usually less clinically obvious because testicular testosterone already dominates.

Adrenal androgen deficiency can occur in adrenal insufficiency or after removal or suppression of adrenal function. In women, this may contribute to reduced libido and fatigue, although the clinical significance of isolated adrenal androgen deficiency is still under investigation.

Recognizing the role of adrenal androgens is important for interpreting androgen-related symptoms, especially in women with hirsutism, acne, or irregular menses. It also highlights the contribution of the adrenal gland to sex-steroid metabolism beyond the gonads.

5.5 Catecholamines: epinephrine and norepinephrine

The adrenal medulla produces and releases catecholamines, primarily epinephrine (adrenaline) and norepinephrine (noradrenaline). These hormones are part of the sympathetic nervous system and are essential for the body's rapid response to stress.

Epinephrine and norepinephrine are synthesized from the amino acid tyrosine. Tyrosine is converted to dihydroxyphenylalanine (DOPA) by the enzyme tyrosine hydroxylase, the rate-limiting step in catecholamine synthesis. DOPA is then converted to dopamine, which is transported into vesicles and converted to norepinephrine. In chromaffin cells, norepinephrine is further converted to epinephrine by the enzyme phenylethanolamine-N-methyl transferase (PNMT).

Catecholamine synthesis occurs mainly in the adrenal medulla and in sympathetic nerve terminals throughout the body. In the adrenal medulla, chromaffin cells store large amounts of catecholamines in secretory granules. When sympathetic nerves fire, they release acetylcholine at the synapses on chromaffin cells, which stimulates the release of epinephrine and norepinephrine into the bloodstream.

Catecholamines act on α - and β -adrenergic receptors, which are distributed in many tissues. Epinephrine has relatively equal effects on both α - and β -receptors, while norepinephrine acts mainly on α -receptors. Their actions include:

- **Cardiovascular effects:** increased heart rate, contractility, and cardiac output; vasoconstriction in many vascular beds (raising blood pressure).
- **Metabolic effects:** increased glycogenolysis in liver and muscle, lipolysis in adipose tissue, and release of glucose and fatty acids into the blood.
- **Respiratory effects:** bronchodilation, improving air flow.
- **Sensory and CNS effects:** pupil dilation, reduced gastrointestinal motility, and heightened alertness.

The overall effect of catecholamine release is to prepare the body for immediate physical activity—increasing blood flow to heart and skeletal muscle, providing extra fuel, and sharpening mental focus. This response is adaptive in short-term stress but can be harmful if chronically activated, contributing to hypertension, cardiac arrhythmias, and metabolic disturbance.

Catecholamines are rapidly metabolized by enzymes such as monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT), which break them down in the liver, kidney, and other tissues. Their metabolites, such as metanephrines and vanillylmandelic acid (VMA), can be measured in blood and urine to assess catecholamine excess, as in pheochromocytoma, a tumor of chromaffin cells.

Understanding catecholamine physiology explains the role of the adrenal medulla in stress responses and the pharmacological use of adrenergic agonists and antagonists in clinical practice.

5.6 Adrenal–pituitary axis and circadian rhythm

The adrenal glands are closely linked to the hypothalamic–pituitary–adrenal (HPA) axis, which integrates neural, endocrine, and metabolic signals to regulate glucocorticoid secretion. The HPA axis is a key system for responding to stress and maintaining homeostasis.

The hypothalamus produces corticotropin-releasing hormone (CRH) and vasopressin (ADH) in response to various stimuli, including stress, low blood glucose, inflammation, and circadian signals. These hormones stimulate the anterior pituitary to secrete adrenocorticotrophic hormone (ACTH) into the bloodstream. ACTH travels to the adrenal cortex, where it binds to receptors on cells in the zona fasciculata and zona reticularis, promoting the synthesis and release of cortisol and, to a lesser extent, androgens.

Cortisol exerts negative feedback on the hypothalamus and pituitary, reducing the secretion of CRH and ACTH. This feedback loop helps maintain cortisol levels within a narrow range under normal conditions. However, during acute stress, the negative feedback is temporarily overridden, allowing a surge in cortisol to support adaptation.

Cortisol secretion follows a circadian (diurnal) rhythm, with concentrations highest in the early morning and lowest around midnight. This rhythm is controlled by the suprachiasmatic nucleus (SCN) of the hypothalamus, the body's master circadian clock, which synchronizes the HPA axis with the light–dark cycle. Disruptions in sleep, shift work, or jet lag can alter this rhythm and affect cortisol patterns.

The HPA axis also interacts with other systems. Cytokines released during infection or inflammation stimulate CRH and ACTH secretion, contributing to the “sickness response.” Chronic activation of the HPA axis, as in long-term stress, can lead to dysregulation of immune, metabolic, and neuroendocrine functions. Conversely, HPA axis suppression (e.g., from long-term glucocorticoid therapy) can impair the body's ability to respond to stress. Understanding the adrenal–pituitary axis and its circadian rhythm is essential for interpreting cortisol measurements, evaluating adrenal function, and managing patients on glucocorticoid treatment. It also illustrates the integration of timing, stress, and hormone regulation in physiology.

TABLE 5.3: HPA Axis Flow

Stimulus	Hypothalamus	Pituitary	Adrenal	Cortisol Effect
Stress	CRH ↑	ACTH ↑	Cortisol ↑	↑Glucose, ↓Immune
Feedback	-	↓CRH/ACTH	-	Normal levels

5.7 Cushing's syndrome, Addison's disease, and adrenal tumors

Disorders of the adrenal glands often result from abnormal production of cortisol, aldosterone, or catecholamines. The most important clinical conditions include Cushing's syndrome, Addison's disease, and adrenal tumors such as pheochromocytoma.

Cushing's syndrome is characterized by chronic excess of cortisol, regardless of cause. Common features include central obesity, facial rounding (moon face), buffalo hump, purple striae, thin skin, easy bruising, muscle weakness, hypertension, glucose intolerance or diabetes, and mood changes. The excess cortisol can suppress the immune system, increasing susceptibility to infection, and impair bone metabolism, leading to osteoporosis.

Cushing's syndrome can be exogenous (due to long-term therapeutic use of glucocorticoids) or endogenous. Endogenous forms include Cushing's disease (pituitary ACTH-secreting tumor), ectopic ACTH secretion (from non-pituitary tumors), and adrenal tumors (adenomas or carcinomas producing cortisol). Diagnosis usually involves demonstration of hypercortisolism (elevated 24-hour urinary free cortisol, high late-night salivary cortisol, or loss of normal diurnal rhythm) and determination of the source using ACTH levels and imaging.

Addison's disease (primary adrenal insufficiency) results from destruction or failure of the adrenal cortex, so that secretion of cortisol and, usually, aldosterone is reduced. Patients may present with fatigue, weakness, weight loss, nausea, hypotension, hyperpigmentation (due to elevated ACTH), and salt craving. Acute adrenal crisis (an emergency) can occur during stress, infection, or trauma and is characterized by severe hypotension, dehydration, hypoglycemia, and shock.

Laboratory findings in Addison's disease include low serum cortisol, elevated ACTH, hyponatremia, and hyperkalemia. Treatment requires glucocorticoid replacement (usually hydrocortisone or prednisone) and, when necessary, mineralocorticoid replacement with fludrocortisone.

Adrenal tumors include adenomas (usually benign), carcinomas (rare and malignant), and pheochromocytomas. Adrenal adenomas may be non-functioning (incidentalomas) or functioning, producing excess cortisol, aldosterone, or androgens. Adrenal carcinoma is an aggressive tumor that often causes rapid onset of Cushing's syndrome or combined cortisol and androgen excess.

Pheochromocytoma is a tumor of chromaffin cells in the adrenal medulla (or rarely from extra-adrenal chromaffin tissue) that produces excessive catecholamines, mainly epinephrine and norepinephrine. Patients may present with paroxysmal or sustained

hypertension, headaches, palpitations, sweating, tremor, and anxiety. Diagnosis is based on elevated plasma or urinary catecholamines and their metabolites, confirmed by imaging. Treatment usually involves alpha- and beta-adrenergic blockade before surgical removal of the tumor.

Other adrenal tumors include aldosterone-producing adenomas (in Conn's syndrome) and androgen-producing tumors, which cause hypertension with hypokalemia and hirsutism or virilization, respectively. Imaging (CT or MRI) and hormonal testing are essential to distinguish between benign and malignant lesions and to guide management.

Understanding adrenal disorders is important because they can mimic many other diseases and may present with non-specific symptoms such as fatigue, weight change, or hypertension. Early recognition and appropriate investigation can prevent serious complications and allow effective treatment.

TABLE 5.4: Main disorders of adrenal function

Disorder	Hormone abnormality	Typical clinical features
Cushing's syndrome	Excess cortisol	Central obesity, moon face, striae, hypertension
Addison's disease	Deficiency of cortisol $\pm$ aldosterone	Fatigue, weight loss, hypotension, hyperpigmentation
Primary hyperaldosteronism	Excess aldosterone	Hypertension, hypokalemia
Pheochromocytoma	Excess catecholamines	Paroxysmal hypertension, headache, sweating, tremor

5.8 Endocrine aspects of stress and adaptation

The adrenal glands, especially through the secretion of cortisol and catecholamines, play a central role in the body's response to stress. Stress can be physical (injury, infection,

surgery, starvation) or psychological (anxiety, fear, chronic worry), and the adrenal-pituitary system helps the body adapt by mobilizing energy, maintaining blood pressure, and modulating immune and emotional responses.

Under stress, the hypothalamic–pituitary–adrenal (HPA) axis is activated, leading to increased cortisol secretion, while the sympathetic–adrenal medullary system releases epinephrine and norepinephrine. Together, these hormones increase heart rate and blood pressure, redirect blood flow to vital organs, promote glucose production and availability, and suppress non-essential functions such as digestion, reproduction, and parts of the immune system.

In the short term, this response is adaptive and protective. However, chronic stress and prolonged activation of these systems can lead to harmful effects, including sustained hypertension, insulin resistance, weight gain, immune suppression, mood disorders, and sleep disturbances. These changes link adrenal-mediated stress responses with common conditions such as metabolic syndrome, cardiovascular disease, and psychiatric disorders.

On the other hand, adrenal insufficiency impairs the stress response and can cause weakness, fatigue, hypotension, and vulnerability to illness or trauma. In this state, the body cannot mount an appropriate hormonal response when demands increase.

Understanding the endocrine aspects of stress and adaptation is therefore essential for appreciating how hormones help the body cope with daily challenges and how their imbalance contributes to disease. It also highlights the importance of psychological and behavioral factors in overall health and the need for integrated approaches in prevention and treatment.

KEY CONCEPTS:

- ☒ **Adrenal Cortex Zones:** Glomerulosa (Aldosterone), Fasciculata (Cortisol), Reticularis (DHEA)
- ☒ **HPA Axis:** Stress → CRH → ACTH → Cortisol (negative feedback)
- ☒ **Medulla:** Chromaffin cells → Epinephrine/Norepinephrine (sympathetic stimulation)
- ☒ **Mineralocorticoids:** Na⁺ retention → ↑BP (RAAS + ACTH minor)
- ☒ **Glucocorticoids:** ↑Glucose, ↓Immune (circadian rhythm: peak AM)

- **Clinical Correlation 5.1: Addison's Crisis**

32M: Severe fatigue, vomiting, BP 80/50, skin pigmentation.

Post-infection. Labs: Na 128 ↓, K 5.8 ↑↑, Cortisol <2 ↓↓.

Diagnosis: Primary adrenal insufficiency (Addison's)

Treatment: IV Hydrocortisone 100mg + Normal saline

- **Clinical Correlation 5.2: Cushing's Syndrome**

45F: Weight gain central, moon face, purple striae, hypertension.

Labs: Cortisol 30 µg/dL ↑↑ (AM), no suppression on low-dose dex.

Diagnosis: Cushing's syndrome

Treatment: Investigate source (pituitary/adrenal)

- **Clinical Correlation 5.3: Pheochromocytoma**

35M: episodic headache, sweating, palpitations

Episodes 3x/week, BP 220/120 during attacks

Labs: Urinary metanephrines ↑↑↑, CT: 4cm adrenal mass

Diagnosis: Pheochromocytoma

Treatment: α-blocker (Phenoxybenzamine) → Surgery

Chapter 6: Pancreatic Hormones and Metabolism

6.1 Pancreatic islet cell types and histology

The pancreas is a dual-function organ: it has both **exocrine** and **endocrine** components. The exocrine pancreas secretes digestive enzymes into the duodenum, while the endocrine pancreas consists of clusters of cells called the **islets of Langerhans**, which produce hormones that regulate blood glucose and metabolism.

Islets are scattered throughout the pancreatic tissue and vary in size and number. They are more abundant in the **tail** of the pancreas than in the head. Each islet contains several types of hormone-producing cells arranged in a characteristic pattern.

The main endocrine cell types are:

- **Beta cells (β -cells):** These are the most numerous islet cells. They produce and secrete **insulin**, the primary hormone responsible for lowering blood glucose. Beta cells are typically located in the central part of the islet.
- **Alpha cells (α -cells):** These cells produce **glucagon**, which raises blood glucose. They are usually located at the periphery of the islet.
- **Delta cells (δ -cells):** These cells secrete **somatostatin**, which inhibits the secretion of both insulin and glucagon and modulates gastrointestinal function.
- **PP cells (F cells):** These cells produce **pancreatic polypeptide**, which influences pancreatic exocrine secretion and gastrointestinal motility.


Epsilon cells (ϵ -cells): A small population of cells that produce **ghrelin**, a hormone involved in appetite regulation.

In addition to islet cells, the pancreas contains ducts, acinar cells (for exocrine secretion), and a rich network of blood vessels and nerves. Blood from the islets drains into the hepatic portal vein, so pancreatic hormones reach the liver before entering the general

circulation. This arrangement is important for the rapid regulation of hepatic glucose metabolism.

Understanding the histology and cell types of the pancreatic islets provides the foundation for studying the physiology of insulin, glucagon, and other islet hormones and their roles in glucose homeostasis.

**Fig 7.2: Pancreas – Pancreatic Islets (Islets of Langerhans)
Alpha, Beta and Delta Cells**



6.2 Insulin: structure, secretion and regulation

Insulin is a peptide hormone produced by the beta cells of the pancreatic islets. It is essential for the regulation of carbohydrate, lipid, and protein metabolism and for the maintenance of normal blood glucose levels.

The structure of insulin consists of two polypeptide chains, the A chain and the B chain, connected by disulfide bonds. Insulin is synthesized as a larger precursor called preproinsulin, which is rapidly converted to proinsulin in the endoplasmic reticulum. Proinsulin is then packaged into secretory granules, where proteolytic enzymes cleave it to yield mature insulin and a fragment called C-peptide. Both insulin and C-peptide are released into the blood when the granules fuse with the cell membrane.

Insulin secretion is tightly regulated by blood glucose concentration. When blood glucose rises after a meal, glucose enters beta cells through specific transporters, is metabolized, and leads to an increase in the intracellular ATP/ADP ratio. This inhibits ATP-sensitive potassium channels, causing membrane depolarization, opening of voltage-gated calcium channels, and an influx of calcium. The rise in intracellular calcium triggers the exocytosis of insulin-containing granules.

In addition to glucose, several other factors influence insulin secretion:

- Amino acids (especially arginine and leucine) stimulate insulin release.
- Gastrointestinal hormones such as incretins (GLP-1 and GIP) enhance glucose-stimulated insulin secretion.
- Parasympathetic stimulation (vagal activity) increases insulin release, especially in the cephalic and gastric phases of a meal.
- Sympathetic stimulation and stress hormones (epinephrine, cortisol) generally suppress insulin secretion and favor catabolic responses.

Feedback regulation of insulin also involves **somatostatin** from delta cells, which inhibits both insulin and glucagon secretion. Additionally, insulin itself and other metabolic signals modulate beta-cell function over time.

Dysregulation of insulin secretion is central to disorders such as **diabetes mellitus** and hypoglycemia. Understanding the structure, synthesis, and regulation of insulin is therefore crucial for interpreting glucose metabolism and designing therapeutic strategies.

6.3 Insulin receptors and intracellular signaling

Insulin exerts its effects by binding to specific insulin receptors on the surface of target cells. These receptors are transmembrane glycoproteins present in many tissues, especially liver, skeletal muscle, and adipose tissue, as well as in the brain and other organs.

The insulin receptor is a heterotetrameric protein composed of two extracellular α -subunits and two transmembrane β -subunits. The α -subunits contain the insulin-binding site, while the β -subunits possess intrinsic tyrosine kinase activity. When

insulin binds, it induces a conformational change that activates the tyrosine kinase, leading to autophosphorylation of the β -subunit and phosphorylation of intracellular substrate proteins.

One of the main substrates is the insulin receptor substrate (IRS) family of proteins. IRS proteins then interact with various signaling molecules, including phosphatidylinositol 3-kinase (PI3K) and Grb2/SOS complexes, which activate different downstream pathways.

The PI3K–Akt pathway is the primary metabolic signaling route. Activation of PI3K leads to the production of phosphoinositide lipids, which recruit and activate Akt (protein kinase B). Akt then phosphorylates several target proteins involved in:

- **Glucose uptake:** Akt promotes the translocation of **GLUT4 glucose transporters** from intracellular vesicles to the cell membrane in muscle and fat cells, allowing glucose to enter.
- **Glycogen synthesis:** Akt inhibits **glycogen synthase kinase-3 (GSK-3)**, enhancing glycogen synthase activity and glycogen storage.
- **Protein synthesis and cell growth:** Akt stimulates protein synthesis and cell growth through mammalian target of rapamycin (mTOR) signaling.
- **Lipid metabolism:** Akt suppresses lipolysis and promotes lipogenesis in adipose tissue.

Another important pathway is the Ras–MAP kinase pathway, which is more involved in growth, proliferation, and differentiation than in acute metabolic responses. Insulin binding to its receptor activates Ras, which initiates a cascade of kinases (Raf, MEK, ERK) that regulate gene expression and cell growth.

Dysfunction of insulin receptors or signaling molecules contributes to insulin resistance, a hallmark of type 2 diabetes and metabolic syndrome. In contrast, overactivation of these pathways can promote cell proliferation and has been implicated in certain cancers.

Understanding insulin receptors and intracellular signaling explains how a single hormone can regulate multiple cellular processes and why defects in this system lead to widespread metabolic disturbances.

6.4 Metabolic actions of insulin in liver, muscle, and adipose tissue

Insulin is the principal hormone that lowers blood glucose and promotes the storage of energy. Its actions differ somewhat among tissues, but the overall effect is to shift the body from a catabolic (fasting) to an anabolic (fed) state.

In the liver, insulin exerts several key effects:

- It inhibits gluconeogenesis (the production of glucose from non-carbohydrate precursors) and glycogenolysis (the breakdown of glycogen to glucose).
- It promotes glycogen synthesis by activating glycogen synthase and inhibiting glycogen phosphorylase.
- It stimulates lipogenesis (fat synthesis) and the conversion of excess glucose into fatty acids and triglycerides, which are packaged as very-low-density lipoproteins (VLDL) for export.

As a result, insulin reduces hepatic glucose output and promotes the storage of glucose as glycogen and fat.

In skeletal muscle, insulin:

- Increases glucose uptake by promoting the translocation of GLUT4 transporters to the cell membrane.
- Stimulates glycogen synthesis and protein synthesis.
- Inhibits protein breakdown and promotes amino acid uptake for muscle growth and repair.

Muscle is a major site of glucose disposal after meals, and insulin-dependent glucose uptake here is crucial for postprandial glucose lowering.

In adipose tissue, insulin:

- Increases glucose uptake via GLUT4.
- Promotes lipogenesis and the storage of triglycerides in adipocytes.
- Inhibits lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol.

By reducing circulating free fatty acids and promoting fat storage, insulin helps to lower the availability of alternative fuels and favours carbohydrate utilization.

In addition, insulin has effects in other tissues. In the brain, it influences appetite, cognition, and energy balance. In the kidney, it modulates sodium reabsorption and blood pressure. Chronic hyperinsulinemia can contribute to hypertension and cardiovascular disease.

Impaired insulin action in any of these tissues contributes to hyperglycemia, dyslipidemia, and obesity, which are common features of diabetes and metabolic syndrome. Understanding tissue-specific actions of insulin helps explain the pathophysiology of these conditions and the rationale for therapeutic interventions.

TABLE 6.1: Insulin Signaling Pathway

Step	Component	Effect
Binding	Insulin Receptor (RTK)	Autophosphorylation
Adapter	IRS-1/2	PI3K activation
Key Enzyme	PI3K → Akt	GLUT4 translocation
Targets	GSK3 ↓, FoxO ↓	Glycogen ↑, Gluconeogenesis ↓

6.5 Glucagon and other counter-regulatory hormones

When blood glucose falls, glucagon, secreted by pancreatic alpha cells, acts as the primary counter-regulatory hormone. It works with other hormones to increase blood glucose and prevent hypoglycemia.

Glucagon is a 29-amino-acid peptide hormone. Its secretion is stimulated by low blood glucose, sympathetic stimulation, exercise, and certain amino acids (especially alanine). Conversely, high glucose, insulin, and somatostatin suppress glucagon release.

The main actions of glucagon occur in the liver:

- It promotes glycogenolysis, the breakdown of glycogen to glucose.
- It stimulates gluconeogenesis, the production of glucose from amino acids and other precursors.
- It increases hepatic glucose output into the bloodstream.

These effects raise blood glucose and provide fuel for the brain and other glucose-dependent tissues during fasting or exercise.

Other counter-regulatory hormones include:

- **Epinephrine and norepinephrine:** Released by the adrenal medulla and sympathetic nerves, they increase glycogenolysis in liver and muscle, promote lipolysis, and stimulate glucagon secretion while inhibiting insulin release.
- **Cortisol:** A glucocorticoid that increases gluconeogenesis, protein breakdown, and lipolysis, providing substrates for glucose production.
- **Growth hormone (GH):** It promotes lipolysis and insulin resistance, sparing glucose for vital organs.

TABLE 6.2: Main actions of insulin and glucagon in carbohydrate and lipid metabolism

Process	Effect of insulin	Effect of glucagon
Blood glucose level	Decreases	Increases
Glycogen synthesis	Increases (liver and muscle)	Inhibits
Glycogenolysis	Inhibits	Increases (liver)
Gluconeogenesis	Inhibits	Increases (liver)
Glycolysis	Increases	May decrease
Lipogenesis	Increases (fat storage)	Inhibits
Lipolysis	Inhibits (fat breakdown)	Increases (adipose and liver)
Ketogenesis	Inhibits	Promotes (via fatty acid oxidation)


These hormones act synergistically to defend against hypoglycemia. In healthy individuals, their coordinated release quickly restores normal glucose levels. However, in patients with diabetes, especially those on insulin or insulin-secretagogue therapy,

impaired glucagon responses and other counter-regulatory defects can increase the risk of severe hypoglycemia.

Understanding glucagon and counter-regulatory hormones is essential for interpreting glucose homeostasis and for managing hypoglycemia in clinical practice.

TABLE 6.3: Insulin vs Glucagon Actions

Process	Insulin (Fed State)	Glucagon (Fasting State)
Blood Glucose	↓	↑
Liver Glycogen	Synthesis ↑	Breakdown ↑
Gluconeogenesis	Inhibits	Stimulates
Lipolysis (Fat)	Inhibits	Stimulates
Protein Breakdown	Inhibits	Stimulates



6.6 Integrated regulation of blood glucose

Blood glucose levels are maintained within a narrow range through the coordinated action of insulin, glucagon, and other hormones. This balance, known as glucose homeostasis, involves multiple tissues and feedback mechanisms.

In the fed state, after a meal, blood glucose rises. This stimulates insulin secretion and suppresses glucagon release. Insulin promotes glucose uptake by muscle and adipose tissue, glycogen synthesis in liver and muscle, and storage of glucose as fat. At the same time, insulin inhibits hepatic glucose production. These actions lower blood glucose and store energy for later use.

In the fasting state, blood glucose tends to fall. This stimulates glucagon secretion and reduces insulin release. Glucagon increases hepatic glycogenolysis and gluconeogenesis, raising blood glucose. Counter-regulatory hormones such as epinephrine, cortisol, and growth hormone support this process by providing substrates and enhancing glucose production.

The brain, red blood cells, and some other tissues depend almost entirely on glucose for energy. To protect these tissues, the body tightly regulates glucose availability. The liver acts as a glucose reservoir, storing glycogen and releasing glucose when needed. The pancreas senses blood glucose and adjusts insulin and glucagon secretion accordingly.

Disturbances in this integrated system lead to disorders such as hyperglycemia and hypoglycemia. In diabetes mellitus, insulin deficiency or resistance impairs glucose uptake and storage, while glucagon excess may increase hepatic glucose output. In insulinoma or other causes of hyperinsulinism, excessive insulin secretion causes hypoglycemia.

Understanding the integrated regulation of blood glucose helps explain the pathophysiology of diabetes, hypoglycemia, and related metabolic disorders. It also provides the basis for therapeutic strategies that target insulin, glucagon, and other hormones to restore normal glucose control.

6.7 Biology of diabetes mellitus: type 1 and type 2

Diabetes mellitus is a group of metabolic disorders characterized by chronic hyperglycemia due to defects in insulin secretion, insulin action, or both. The two main forms are type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM).

Type 1 diabetes is an autoimmune disease in which the immune system attacks and destroys pancreatic beta cells. This leads to an absolute deficiency of insulin. Type 1 diabetes usually develops in children or young adults, although it can occur at any age. Patients present with symptoms such as polyuria (frequent urination), polydipsia (excessive thirst), polyphagia (excessive hunger), weight loss, and fatigue. In severe cases, diabetic ketoacidosis (DKA) may occur, characterized by hyperglycemia, ketonemia, and metabolic acidosis.

The cause of type 1 diabetes involves genetic susceptibility and environmental triggers, such as viral infections, that initiate an autoimmune response against beta cells. Autoantibodies against insulin, glutamic acid decarboxylase (GAD), and other islet antigens are often present. Without insulin replacement, patients cannot survive.

Type 2 diabetes is characterized by insulin resistance and relative insulin deficiency. Insulin resistance means that tissues such as muscle, liver, and adipose tissue respond poorly to insulin, so higher insulin levels are needed to maintain normal glucose. Over time, beta cells cannot compensate adequately, leading to declining insulin secretion and rising blood glucose. Type 2 diabetes is strongly associated with obesity, sedentary lifestyle, genetic factors, and older age.

Patients with type 2 diabetes may be asymptomatic for years or present with milder symptoms such as fatigue, blurred vision, or recurrent infections. Long-term complications include microvascular disease (retinopathy, nephropathy, neuropathy) and macrovascular disease (coronary artery disease, stroke, peripheral arterial disease). These complications arise from chronic hyperglycemia, hypertension, dyslipidemia, and other metabolic abnormalities.

Both types of diabetes require careful management, including lifestyle modification, medications, and, in type 1 diabetes, insulin therapy. Understanding their biology is essential for prevention, early detection, and treatment to reduce the burden of complications.

TABLE 6.4: Key features of type 1 and type 2 diabetes mellitus

Feature	Type 1 diabetes mellitus (T1DM)	Type 2 diabetes mellitus (T2DM)
Main defect	Absolute insulin deficiency (autoimmune beta-cell destruction)	Insulin resistance + relative insulin deficiency
Typical age of onset	Often childhood or young adulthood	Usually adulthood; increasing in younger people
Body weight	Often normal or low	Often overweight or obese
Autoantibodies	Usually present (GAD, IA-2, etc.)	Absent
Ketosis tendency	High risk of ketoacidosis without insulin	Less common; may occur in stress or severe illness
Initial treatment	Insulin required from diagnosis	Lifestyle + oral drugs ± insulin later
Associated conditions	Other autoimmune diseases possible	Hypertension, dyslipidemia, metabolic syndrome, PCOS, etc.

6.8 Hypoglycemia and its endocrine causes

Hypoglycemia is defined as abnormally low blood glucose, typically below 70 mg/dL (3.9 mmol/L). It can cause symptoms such as palpitations, tremor, sweating, hunger, anxiety, confusion, seizures, and, if untreated, coma and death.

The body has several defenses against hypoglycemia. A fall in blood glucose stimulates glucagon and epinephrine secretion, which increase hepatic glucose production and release. These hormones also trigger autonomic symptoms that alert the person to eat or drink. With recurrent hypoglycemia, especially in patients with diabetes, these defenses may become impaired, leading to hypoglycemia unawareness.

Endocrine causes of hypoglycemia include:

- **Insulinoma:** A rare tumor of pancreatic beta cells that secretes insulin autonomously, causing fasting hypoglycemia. Symptoms often occur before meals or during fasting and can be relieved by eating. Diagnosis usually involves demonstration of inappropriately high insulin and C-peptide levels during hypoglycemia.
- **Exogenous insulin or insulin-secretagogue therapy:** Overdose or mismatch between insulin dose, food intake, and activity can cause hypoglycemia. This is a common problem in patients with diabetes.
- **Adrenal insufficiency (Addison's disease):** Deficiency of cortisol impairs gluconeogenesis and reduces the counter-regulatory response to hypoglycemia.
- **Severe liver disease:** Impaired glycogen storage and gluconeogenesis reduce glucose availability.
- **Pituitary or hypothalamic insufficiency:** Deficiency of growth hormone and cortisol can impair glucose counter-regulation.

Non-endocrine causes of hypoglycemia include prolonged fasting, alcohol, certain medications, and critical illness. Understanding endocrine causes is important for diagnosing and treating hypoglycemia, especially when it occurs in the fasting state or in patients without diabetes.

Recognizing and preventing hypoglycemia is crucial in managing diabetes and other endocrine disorders. It also highlights the importance of balanced hormone action in maintaining glucose homeostasis.

KEY CONCEPTS:

- ☒ **Islet cells:** β (Insulin, center), α (Glucagon, periphery), δ (Somatostatin), PP (Polypeptide)
- ☒ **Insulin secretion:** Glucose $\rightarrow$ $\uparrow$ ATP $\rightarrow$ Close K-ATP $\rightarrow$ Depolarization $\rightarrow$ Ca^{2+} $\rightarrow$ Exocytosis
- ☒ **Insulin actions:** Liver ($\downarrow$ Gluconeogenesis), Muscle/Fat ($\uparrow$ GLUT4), Adipose ($\downarrow$ Lipolysis)
- ☒ **Counter-regulatory:** Glucagon ($\uparrow$ Glucose), Epinephrine/Cortisol/GH (spare glucose)
- ☒ **Diabetes:** T1 (β -cell destruction), T2 (resistance + β -failure)

TABLE 6.5: Type 1 vs Type 2 Diabetes

Feature	Type 1 (T1DM)	Type 2 (T2DM)
Defect	No insulin (autoimmune)	Resistance + relative deficiency
Age	Child/Young adult	Adult (rising in youth)
Weight	Normal/low	Obese
Ketosis Risk	High (DKA)	Low
Treatment	Insulin only	Lifestyle + Oral drugs $\pm$ Insulin

- **Clinical Correlation 6.1: New Onset Type 1 Diabetes**

12F: polyuria, thirst, weight loss 4kg, nausea

Random glucose 450 mg/dL, urine ketones +++

Diagnosis: Type 1 diabetes (DKA)

Treatment: IV insulin + fluids + K^+

- **Clinical Correlation 6.2: Type 2 Diabetes**

52M: fatigue, blurred vision, overweight (BMI 32)

Random glucose 280 mg/dL, HbA1c 9.2% ↑↑

No ketones, normal C-peptide

Diagnosis: Type 2 diabetes mellitus

Treatment: Metformin 1g BD + lifestyle

- **Clinical Correlation 6.3: Insulinoma**

45M: fasting confusion, sweating, glucose 45 mg/dL

Insulin 25 µU/mL ↑, C-peptide ↑ during hypo

Diagnosis: Insulinoma

Treatment: Surgery after localization

Chapter 7: Reproductive and Growth Endocrinology

7.1 Gonadotropins and gonadal steroids

The reproductive system is regulated by hormones from the hypothalamus, pituitary, and gonads. The key pituitary hormones are follicle-stimulating hormone (FSH) and luteinizing hormone (LH), collectively called gonadotropins. The main gonadal hormones are estrogens, progesterone, and androgens such as testosterone.

Gonadotropin secretion is controlled by gonadotropin-releasing hormone (GnRH) from the hypothalamus. GnRH is released in a pulsatile pattern into the hypothalamic–hypophyseal portal blood and stimulates the anterior pituitary to secrete FSH and LH. The frequency and amplitude of GnRH pulses influence the relative amounts of FSH and LH, which in turn regulate follicular development, ovulation, and steroid production.

In the testes, FSH acts on Sertoli cells to support spermatogenesis, while LH acts on Leydig cells to stimulate the synthesis and secretion of testosterone. Testosterone promotes male sexual development, secondary sexual characteristics, and maintenance of libido and fertility. It also exerts negative feedback on the hypothalamus and pituitary, helping to maintain stable hormone levels.

In the ovaries, FSH stimulates the growth and maturation of ovarian follicles and the production of estradiol, the main estrogen. Estradiol supports the development of female reproductive organs, the menstrual cycle, and secondary sexual characteristics. LH triggers ovulation and promotes the formation of the corpus luteum, which secretes progesterone and additional estrogen. Progesterone prepares the endometrium for implantation and helps maintain early pregnancy.

Gonadal steroids act on target tissues by binding to intracellular receptors that regulate gene expression. Effects include regulation of the menstrual cycle, preparation of the uterus and breast for pregnancy, development of secondary sexual characteristics, and modulation of behavior and mood. Understanding the actions of gonadotropins and

gonadal steroids is essential for studying reproductive physiology, infertility, and disorders of sexual development.

TABLE 7.1: Main reproductive hormones and their principal sources and actions

Hormone	Main source	Main actions (simple)
GnRH	Hypothalamus	Stimulates pituitary to release FSH and LH
FSH	Anterior pituitary	Stimulates follicular growth (females) and spermatogenesis (males)
LH	Anterior pituitary	Triggers ovulation and corpus luteum formation (females); stimulates testosterone (males)
Testosterone	Testes (Leydig cells)	Male sexual development, libido, spermatogenesis, muscle mass, bone density
Estradiol	Ovaries (follicles, corpus luteum)	Female sexual development, menstrual cycle, endometrial proliferation, bone health
Progesterone	Corpus luteum, placenta	Prepares and maintains endometrium, supports early pregnancy, prepares breast
Inhibin	Ovaries (granulosa cells), testes (Sertoli cells)	Suppresses FSH secretion (negative feedback)
Human chorionic gonadotropin (hCG)	Placenta	Maintains corpus luteum in early pregnancy, used in pregnancy tests

7.2 Male reproductive endocrinology: testosterone and spermatogenesis

Male reproductive endocrinology centers on the testes and the hypothalamic–pituitary–gonadal (HPG) axis. The primary male sex steroid is testosterone, produced mainly by Leydig cells in the testes under the influence of luteinizing hormone (LH).

Testosterone has multiple functions. During fetal life, it directs the development of male internal and external genitalia. At puberty, rising testosterone levels stimulate the growth of the penis and testes, the development of secondary sexual characteristics such as facial and body hair, deepening of the voice, and increased muscle mass. In adulthood, testosterone maintains libido, erectile function, and fertility, as well as normal bone and muscle mass.

Spermatogenesis, the production of sperm in the seminiferous tubules, requires the coordinated action of FSH and testosterone. FSH acts on Sertoli cells to support the maturation of germ cells, while testosterone, produced locally in high concentrations under LH stimulation, is essential for the completion of spermatogenesis. Sertoli cells also secrete inhibin, which feeds back to the pituitary to inhibit FSH secretion, providing a regulatory loop.

Regulation of the male HPG axis involves negative feedback. Rising testosterone levels inhibit the secretion of GnRH and LH, while inhibin suppresses FSH. This keeps hormone levels within a narrow range and prevents excessive stimulation of the testes. Disruptions in this system can lead to hypogonadism, infertility, or disorders of sexual development.

Understanding male reproductive endocrinology is important for diagnosing and managing conditions such as low testosterone, infertility, and delayed or absent puberty. It also highlights the interaction between hormonal, genetic, and environmental factors in male reproductive health.

7.3 Female reproductive endocrinology: the ovarian cycle and hormones

Female reproductive endocrinology focuses on the cyclic regulation of the ovaries and the uterus by gonadotropins and sex steroids. The sequence of events is known as the menstrual cycle, which typically lasts about 28 days and consists of the follicular phase, ovulation, and luteal phase.

The cycle begins with the early follicular phase, when FSH stimulates the growth of several ovarian follicles. One follicle becomes dominant and produces increasing amounts of estradiol. Rising estradiol levels cause the endometrium to proliferate and prepare for potential implantation. Estradiol also initially exerts negative feedback on the hypothalamus and pituitary, keeping FSH and LH secretion low.

As the dominant follicle matures, estradiol levels continue to rise. At a critical threshold, estradiol switches to positive feedback, leading to a surge in LH and, to a lesser extent, FSH. This LH surge triggers ovulation, the release of the oocyte from the follicle. After ovulation, the remaining follicular tissue forms the corpus luteum, which secretes progesterone and estradiol.

During the luteal phase, progesterone induces secretory changes in the endometrium, making it suitable for implantation. If pregnancy does not occur, the corpus luteum regresses, progesterone and estradiol levels fall, and the endometrium is shed as menstruation. The cycle then repeats. If pregnancy occurs, the placenta produces human chorionic gonadotropin (hCG), which maintains the corpus luteum and its hormone production until the placenta takes over.

Disorders of the menstrual cycle include amenorrhea, oligomenorrhea, dysmenorrhea, and polycystic ovary syndrome (PCOS). These conditions can result from hormonal imbalances, stress, weight changes, or other factors. Understanding female reproductive endocrinology is essential for diagnosing and treating menstrual disorders, infertility, and reproductive-age health issues.


7.4 Puberty and disorders of pubertal development

Puberty is the period of transition from childhood to sexual maturity, characterized by the activation of the hypothalamic–pituitary–gonadal axis and the development of secondary sexual characteristics. It is initiated when the hypothalamus increases the pulsatility of GnRH secretion, leading to increased FSH and LH release and stimulation of gonadal steroid production.

In females, the first sign of puberty is usually breast development (thelarche), followed by the growth of pubic hair and, later, menarche (the first menstrual period). In males, testicular enlargement is typically the first sign, followed by penis growth, pubic hair, voice deepening, and increased muscle mass. Puberty usually begins between ages 8 and

13 in girls and 9 and 14 in boys, but there is wide normal variation influenced by genetics, nutrition, and environmental factors.

Fig 7.1: Gonadal axis (GnRH-FSH-LH) and menstrual cycle



Precocious puberty is the onset of pubertal changes before age 8 in girls or 9 in boys. It can be central (true precocious puberty, with activation of the HPG axis) or peripheral (due to exogenous hormones or tumors producing sex steroids). Delayed puberty is the absence of pubertal development by age 13 in girls or 14 in boys. Causes include constitutional delay, chronic illness, undernutrition, hypogonadism, or genetic disorders.

Evaluation of pubertal disorders involves detailed history, physical examination, assessment of growth and bone age, and measurement of hormone levels. Treatment depends on the cause and may include reassurance, hormone replacement, or intervention for underlying disease. Understanding the endocrinology of puberty helps to distinguish normal variation from pathological conditions and guide appropriate management.

Table 7.2: Key differences between male and female reproductive endocrinology

Feature	Male (testicular axis)	Female (ovarian axis)
Main sex steroids	Testosterone	Estradiol and progesterone
Main pituitary actions	FSH → Sertoli cells; LH → Leydig cells	FSH → follicular growth; LH → ovulation, corpus luteum
Main pattern of hormone pulses	Relatively continuous, slow pubertal onset	Cyclic (menstrual cycle: follicular, ovulatory, luteal phases)
First pubertal sign	Testicular enlargement	Breast budding (thelarche)
Endocrine-aging highlight	Gradual decline in testosterone (andropause)	Sudden fall in estrogen (menopause)

7.5 Infertility and common reproductive endocrinopathies

Infertility is the inability to achieve pregnancy after one year of regular unprotected intercourse. It affects both males and females and often involves endocrine factors. The hypothalamic–pituitary–gonadal axis is central to reproductive function, and disturbances in hormone secretion or action can impair fertility.

In females, common causes include anovulation, polycystic ovary syndrome (PCOS), hypothalamic amenorrhea (due to stress, weight loss, or excessive exercise), and premature ovarian insufficiency (POI). PCOS is characterized by irregular or absent periods, clinical or biochemical signs of hyperandrogenism (such as hirsutism or acne), and polycystic-appearing ovaries on ultrasound. The underlying endocrine disturbance involves elevated androgens, insulin resistance, and abnormal gonadotropin levels.

In males, infertility may result from hypogonadotropic hypogonadism, primary testicular failure, or obstructive causes. Hypogonadotropic hypogonadism involves deficient

GnRH or gonadotropin secretion, leading to low testosterone and impaired spermatogenesis. Primary testicular failure is characterized by high FSH and LH levels and low testosterone, indicating testicular damage.

Diagnosis of infertility usually includes semen analysis in males and assessment of ovulation, ovarian reserve, and tubal patency in females. Hormonal evaluation includes measurements of FSH, LH, estradiol, testosterone, prolactin, and thyroid hormones. Management may involve lifestyle modification, ovulation induction, assisted reproductive technologies, or treatment of underlying endocrine disorders. Understanding reproductive endocrinopathies is essential for effective evaluation and management of infertility.

TABLE 7.3: Common reproductive endocrinopathies

Condition	Main hormone abnormality	Typical clinical features (short)
Polycystic ovary syndrome (PCOS)	Hyperandrogenism, insulin resistance, abnormal gonadotropins	Irregular periods, hirsutism, acne, obesity, infertility
Precocious puberty	Early activation of HPG axis (central or peripheral)	Appearance of pubic/breast development or testicular growth too early
Delayed puberty	Delayed or failed activation of HPG axis	No secondary sexual characteristics at expected age
Hypogonadotropic hypogonadism	Low GnRH / FSH / LH	Low sex steroids, infertility, delayed or absent puberty
Primary gonadal failure	High FSH / LH, low sex steroids (testicular/ovarian)	Infertility, amenorrhea or hypogonadism

7.6 Growth hormone, IGF-1, and disorders of growth

Growth during childhood and adolescence is regulated by growth hormone (GH), insulin-like growth factor-1 (IGF-1), and other hormones. The somatotrophic axis includes the hypothalamus, anterior pituitary, and peripheral tissues, particularly the liver.

The hypothalamus produces growth hormone–releasing hormone (GHRH) and somatostatin (GHIH). GHRH stimulates the pituitary to secrete GH, while somatostatin inhibits its release. GH secretion is pulsatile, with a major surge during deep sleep. In target tissues, especially the liver, GH stimulates the production of IGF-1, which mediates many of GH's growth-promoting effects. IGF-1 circulates bound to carrier proteins and acts on growth plates in bones, muscle, and other tissues to promote cell division and differentiation.

GH also has metabolic actions, including stimulation of lipolysis, increase in free fatty acids, and reduction of glucose uptake, which favor the use of fats for energy and spare glucose. It influences protein metabolism by promoting protein synthesis and reducing breakdown. Together, these effects support tissue growth, repair, and normal body composition.

Disorders of the somatotrophic axis include growth hormone deficiency (GHD), growth hormone excess, and insulin-like growth factor deficiency. GHD in children can lead to short stature and delayed growth, while in adults it may cause reduced muscle mass, increased fat mass, and decreased quality of life. Growth hormone excess in children causes gigantism, while in adults it causes acromegaly, characterized by enlarged hands, feet, facial features, and soft tissue overgrowth. These conditions are usually due to pituitary tumors.

Diagnosis of growth disorders involves auxological assessment (height, weight, growth velocity), imaging, and measurement of GH and IGF-1 levels, often with stimulation or suppression tests. Treatment may include GH replacement for deficiency or medical, surgical, or radiation therapy for excess. Understanding the role of GH and IGF-1 is essential for managing growth disorders and related metabolic complications.

7.7 Endocrinology of pregnancy and placental hormones

During pregnancy, the endocrine system undergoes profound changes to support fetal development and prepare the maternal body for childbirth and lactation. The placenta becomes a major endocrine organ, producing several hormones.

Key placental hormones include:

- Human chorionic gonadotropin (hCG): Produced by trophoblast cells, hCG rescues the corpus luteum after implantation, ensuring continued progesterone and estradiol production. It also supports early pregnancy and is the hormone detected in pregnancy tests.
- Human placental lactogen (hPL), also called human chorionic somatomammotropin: This hormone has growth hormone–like and lactogenic properties, influencing maternal metabolism to favor nutrient availability for the fetus. It promotes lipolysis and insulin resistance, which helps maintain glucose for the growing fetus.
- Progesterone and estrogen: Produced initially by the corpus luteum and later by the placenta, these steroids maintain the uterine lining, suppress maternal immune responses, and prepare the uterus for labor and the mammary glands for lactation.
- Relaxin: Produced by the corpus luteum and placenta, relaxin softens the cervix and pelvic ligaments, facilitating delivery.

The maternal endocrine system adapts to pregnancy by increasing the secretion of cortisol, aldosterone, and renin-angiotensin-aldosterone components, which support blood volume expansion and renal function. Thyroid hormone requirements increase, and changes in binding proteins alter total hormone levels, though free hormone levels are usually maintained. Glucose metabolism is also altered, with increased insulin resistance in late pregnancy to ensure adequate glucose for the fetus; failure to compensate can lead to gestational diabetes.

Understanding the endocrinology of pregnancy is essential for managing normal and complicated pregnancies, interpreting hormonal changes, and diagnosing endocrine disorders that may arise during or after pregnancy.

7.8 Endocrine aging and sex-steroid changes

Aging is associated with changes in the endocrine system, particularly in sex-steroid levels and the hypothalamic–pituitary–gonadal axis. These changes influence body composition, bone density, mood, and sexual function.

In women, the most dramatic change is menopause, the permanent cessation of menstrual cycles, usually occurring around age 50. It results from depletion of ovarian follicles and a decline in estradiol and progesterone production. Climacteric symptoms may include hot flashes, night sweats, vaginal dryness, mood changes, and sleep disturbances. Long-term consequences include increased risk of osteoporosis and cardiovascular disease due to loss of estrogenic protective effects.

In men, aging is associated with a gradual decline in testosterone levels, known as late-onset hypogonadism or andropause. Symptoms may include decreased libido, erectile dysfunction, fatigue, reduced muscle mass, increased fat mass, and mood changes. However, the relationship between declining testosterone and symptoms is more variable than in menopausal women, and not all men require treatment.

Both men and women may experience changes in growth hormone and IGF-1 levels with age, contributing to loss of muscle mass and strength (sarcopenia) and increased fat mass. The hypothalamic–pituitary–adrenal axis also ages, but with more individual variation. Understanding endocrine aging helps in managing age-related symptoms, preventing osteoporosis and metabolic disease, and counseling patients about hormone replacement therapy.

KEY CONCEPTS:

- ☒ **HPG axis:** GnRH (pulsatile) → FSH/LH → Gonadal steroids (negative feedback)
- ☒ **Male:** LH → Leydig (testosterone), FSH → Sertoli (spermatogenesis)
- ☒ **Female:** FSH → follicle/estradiol, LH surge → ovulation → progesterone
- ☒ **Puberty:** Girls (breast 8-13y), Boys (testes 9-14y)
- ☒ **Menopause:** FSH >25 IU/L, hot flushes, osteoporosis

TABLE 7.4: Reproductive Hormones

Hormone	Source	Main Action
GnRH	Hypothalamus	↑FSH/LH (pulsatile)
FSH	Pituitary	Follicles (F), Spermatogenesis (M)
LH	Pituitary	Ovulation/Corpus luteum (F), Testosterone (M)
Testosterone	Leydig cells	Libido, muscle, bone
Estradiol	Ovarian follicles	Endometrium, breast dev.
Progesterone	Corpus luteum	Pregnancy maintenance

TABLE 7.5: Male vs Female

Feature	Male	Female
Steroids	Testosterone	Estradiol + Progesterone
Pituitary	FSH (Sertoli), LH (Leydig)	FSH (follicles), LH (ovulation)
Pattern	Continuous	Cyclic (28 days)
Puberty start	Testes enlarge	Breast budding
Aging	Andropause (gradual)	Menopause (sudden)

TABLE 7.6: Common Disorders

Condition	Hormone Issue	Key Features
PCOS	↑Androgens, LH:FSH >2	Irregular menses, hirsutism
Precocious puberty	Early HPG activation	Pubic hair/breasts <8/9y
Hypogonadism	Low GnRH/FSH/LH	Delayed puberty, infertility
Acromegaly	↑GH/IGF-1	Large hands/feet (adult)

- **Clinical Correlation 7.1: PCOS**

28F: irregular periods, hirsutism, BMI 29, acne

Ultrasound: multiple ovarian cysts

Labs: Testosterone ↑, LH:FSH = 3:1

Diagnosis: Polycystic ovary syndrome

Treatment: OCP + Metformin + Weight loss

- **Clinical Correlation 7.2: Menopause**

51F: hot flushes, night sweats, amenorrhea 1y

Labs: FSH 45 IU/L ↑↑, Estradiol <20 pg/mL ↓↓

Diagnosis: Menopause

Treatment: HRT (if no contraindications)

Chapter 8: Clinical Endocrinology and Emerging Concepts

8.1 Approach to endocrine patients: history, examination and syndromes

Clinical endocrinology focuses on the diagnosis and management of hormone disorders. The approach to an endocrine patient combines history, physical examination, and targeted laboratory testing. The goal is to identify hormone excess or deficiency and to determine the underlying cause.

History taking should focus on symptoms related to major endocrine axes: thyroid, adrenal, pituitary, gonadal, and pancreatic function. Examples include changes in weight, energy, mood, sleep, heat or cold intolerance, menstrual irregularities, sexual function, and blood pressure or glucose abnormalities. A family history of endocrine disorders, autoimmune diseases, or cancer may also be relevant.

Physical examination should assess growth and body proportions, skin, hair, thyroid gland, blood pressure, heart rate, abdominal girth, and signs of hypercortisolism, acromegaly, or thyroid eye disease. Laboratory studies usually include measurements of specific hormones and their regulators, along with imaging when indicated. Results are interpreted in the context of the patient's age, sex, and clinical status.

Understanding the clinical approach helps students and trainees recognize common endocrine presentations and plan appropriate investigations and referrals. It also emphasizes the importance of considering endocrine causes in patients with nonspecific symptoms such as fatigue, weight change, or infertility.

8.2 Laboratory and imaging investigations in endocrinology

Endocrine laboratory evaluation is central to diagnosis. Hormone measurements can be qualitative (normal vs abnormal) or quantitative, and interpretation requires knowledge of circadian rhythms, binding proteins, and interfering factors.

Common tests include:

- I. Thyroid function tests: TSH, free T₄, free T₃, and sometimes thyroid antibodies.
- II. Adrenal function tests: cortisol, ACTH, aldosterone, renin, and 24 hour urinary free cortisol.
- III. Pituitary function tests: GH, IGF 1, prolactin, FSH, LH, and others as indicated.
- IV. Gonadal function tests: testosterone, estradiol, progesterone, and gonadotropins.
- V. Pancreatic and glucose metabolism tests: fasting glucose, HbA1c, oral glucose tolerance test, insulin, C peptide.

Dynamic tests are often necessary. These include suppression or stimulation tests, such as the dexamethasone suppression test for Cushing's syndrome, the oral glucose tolerance test for diabetes, or the insulin tolerance test for growth hormone deficiency. Dynamic tests must be performed carefully to avoid complications.

Interpretation of results requires attention to preanalytic factors, such as time of day, stress, medications, and pregnancy. Reference ranges may vary by sex, age, and assay. Collaboration with laboratory medicine specialists ensures accurate diagnosis and appropriate follow up.

8.2 A Dynamic endocrine testing protocols

Dynamic tests assess pituitary, adrenal, and gonadal reserve by measuring hormone responses to stimulation or suppression. The dexamethasone suppression test (1mg overnight) diagnoses Cushing's syndrome—if cortisol >1.8 µg/dL post-dexamethasone, pituitary/adrenal source confirmed. ACTH stimulation test (250µg cosyntropin IV) evaluates adrenal function; cortisol <18 µg/dL at 60min indicates primary adrenal insufficiency. Insulin tolerance test (insulin 0.1 U/kg IV) remains gold standard for growth hormone deficiency but carries hypoglycemia risk. GnRH stimulation distinguishes hypothalamic vs pituitary hypogonadism. Proper timing, contraindications, and reference ranges are critical for accurate interpretation.

TABLE 8.1: Key Lab Tests

Test	Use	Abnormal Result
TSH + FT4	Thyroid screen	↑TSH ↓FT4 = Hypo; ↓TSH ↑FT4 = Hyper
Cortisol (AM)	Adrenal screen	<5 µg/dL suspicious
Prolactin	Galactorrhea/amenorrhea	>200 ng/mL = Prolactinoma
HbA1c	Diabetes diagnosis	≥6.5% = DM
Dex suppression	Cushing's	No suppression (>1.8 µg/dL)

8.3 Endocrine emergencies

Endocrine emergencies are life threatening conditions that require rapid recognition and treatment. Key examples include diabetic ketoacidosis, hyperosmolar hyperglycemic state, adrenal crisis, thyroid storm, and severe hypoglycemia.

Diabetic ketoacidosis (DKA) combines hyperglycemia, ketosis, and metabolic acidosis, often occurring in type 1 diabetes due to insulin deficiency. Patients present with polyuria, polydipsia, weight loss, nausea, vomiting, abdominal pain, and altered mental status. Management involves fluid resuscitation, insulin infusion, and correction of electrolyte abnormalities, especially potassium.

Hyperosmolar hyperglycemic state occurs mainly in type 2 diabetes and is characterized by severe dehydration and extreme hyperglycemia without significant ketosis. It also requires aggressive fluid and electrolyte replacement and insulin therapy.

Adrenal crisis results from acute cortisol deficiency, often in patients with known adrenal insufficiency who are stressed or infected. Symptoms include hypotension, hypoglycemia, fever, confusion, and shock. Immediate treatment with intravenous hydrocortisone is lifesaving.

Thyroid storm is a rare but severe form of hyperthyroidism, often triggered by infection, surgery, or trauma. It presents with high fever, tachycardia, hypertension or hypotension, agitation, and sometimes heart failure. Treatment involves rapid control of thyroid hormone synthesis and release, beta blockade, and supportive care.

Severe hypoglycemia can occur in patients with diabetes on insulin or insulin secretagogue therapy. It causes sweating, tremor, palpitations, confusion, seizures, and coma if untreated. Initial management is administration of glucose, either orally or intravenously, followed by adjustment of medication and education.

Understanding endocrine emergencies is essential for preventing morbidity and mortality. Early recognition and appropriate intervention can save lives and improve outcomes.

TABLE 8.2: Common endocrine laboratory tests and their main clinical uses

Emergency	Main hormonal abnormality	Typical key features (exam-style)
Diabetic ketoacidosis (DKA)	Insulin deficiency, high blood glucose, ketosis	Hyperglycemia, ketonuria, nausea/vomiting, dehydration, altered mental status
Hyperosmolar hyperglycemic state	Severe hyperglycemia, little ketosis	Extreme dehydration, confusion, very high glucose, often in older adults with type 2 diabetes
Adrenal crisis	Acute cortisol deficiency	Hypotension, hypoglycemia, fever, weakness, abdominal pain, shock
Thyroid storm	Excess thyroid hormone (T_3/T_4)	High fever, tachycardia, anxiety, gastrointestinal symptoms, heart failure
Severe hypoglycemia	Very low blood glucose (often from drugs)	Sweating, tremor, palpitations, confusion, seizures, coma

8.4 Endocrine tumors and syndromes

Endocrine tumors may be benign or malignant and may secrete hormones, causing characteristic syndromes. Examples include pituitary adenomas, thyroid nodules, adrenal tumors, and pancreatic islet cell tumors.

Pituitary adenomas can be non functioning or hormone secreting. Prolactin secreting adenomas cause amenorrhea, galactorrhea, and infertility. ACTH secreting adenomas lead to Cushing's disease, and GH secreting adenomas cause acromegaly or gigantism. Management depends on tumor size, hormone secretion, and symptoms and may involve surgery, radiation, or medical therapy.

Thyroid nodules are common and often benign, but some are malignant. Evaluation includes thyroid function tests, ultrasound, and fine needle aspiration biopsy. Treatment of thyroid cancer includes surgery, radioactive iodine, and thyroid hormone replacement.

Adrenal tumors include adenomas and carcinomas. Aldosterone producing adenomas cause Conn's syndrome, cortisol producing tumors cause Cushing's syndrome, and pheochromocytomas secrete catecholamines and cause hypertension. Imaging and hormone testing guide diagnosis and treatment, often involving surgery.

Pancreatic islet cell tumors may secrete insulin, causing hypoglycemia, or glucagon, causing hyperglycemia and other symptoms. Diagnosis requires demonstration of inappropriate hormone levels during symptomatic episodes and imaging to localize the tumor. Surgical resection is often curative.

Endocrine syndromes may also be genetic, such as multiple endocrine neoplasia types 1 and 2, which involve tumors of the parathyroid, adrenal, and pancreatic tissues. Genetic testing and family screening are important in these conditions.

8.4A Multiple Endocrine Neoplasia (MEN) syndromes

MEN syndromes are autosomal dominant disorders causing multiple endocrine tumors. MEN1 (menin gene) affects "3Ps": parathyroid adenomas (95%, hypercalcemia), pituitary adenomas (prolactinoma/acromegaly), pancreatic NETs (gastrinoma causing refractory ulcers). MEN2A (RET proto-oncogene) includes medullary thyroid carcinoma (MTC, 100%), pheochromocytoma (50%), hyperparathyroidism (30%). MEN2B adds marfanoid habitus and mucosal neuromas. Annual screening (calcium, prolactin, RET mutation) enables early intervention. Prophylactic thyroidectomy prevents MTC mortality in MEN2.

TABLE 8.3: MEN Syndromes

Syndrome	Tumors	Key Hormone	Screening
MEN1	3Ps: Pituitary, Parathyroid, Pancreas	↑PTH, ↑PRL, ↑Gastrin	Annual Ca, PTH, PRL
MEN2A	MTC + Pheo + Hyperpara	↑Calcitonin, ↑Catecholamines	RET gene, annual Ca
MEN2B	MTC + Pheo + Mucosal neuromas	↑Calcitonin	RET gene testing

8.5 Endocrine effects of drugs and exogenous hormones

Many drugs and exogenous hormones profoundly affect endocrine function. Examples include glucocorticoids, thyroid hormone, insulin, oral contraceptives, and anabolic steroids.

Glucocorticoids, used for inflammation and autoimmune diseases, can cause iatrogenic Cushing's syndrome with weight gain, hypertension, hyperglycemia, and osteoporosis. Long term use suppresses the hypothalamic–pituitary–adrenal axis, leading to adrenal insufficiency if stopped abruptly.

Thyroid hormone is used to treat hypothyroidism and prevent goiter but can cause hyperthyroidism if dosage is excessive. Careful monitoring of TSH and free T₄ is essential.

Insulin and oral hypoglycemic agents are mainstays of diabetes management but can cause hypoglycemia. Newer agents, such as GLP 1 receptor agonists and SGLT 2 inhibitors, have additional effects on weight, cardiovascular risk, and renal function.

Oral contraceptives and hormone replacement therapy contain estrogen and progestin and can influence coagulation, lipid metabolism, and breast cancer risk. Their use requires individualized risk–benefit assessment.

Anabolic steroids, used illicitly for performance enhancement, suppress the hypothalamic–pituitary–gonadal axis, leading to infertility, testicular atrophy, and other adverse effects. They also increase cardiovascular risk.

Understanding drug effects on endocrine function is crucial for safe prescribing and for recognizing iatrogenic endocrine disorders in clinical practice.

8.5A Hormone replacement therapy guidelines

HRT restores physiologic hormone levels in deficiency states. Levothyroxine dosing begins at 1.6 µg/kg/day, targeting TSH 0.5-2.5 mIU/L; elderly start 25-50µg with slow titration. Hydrocortisone 15-25mg/day (2/3 AM, 1/3 PM) mimics circadian rhythm; fludrocortisone 0.1mg for mineralocorticoid replacement in Addison's. Testosterone IM 75-100mg q2 weeks or gels maintain mid-normal range; monitor hematocrit (>54% = stop). Estradiol transdermal preferred in menopause (lower VTE risk vs oral). Regular monitoring prevents over-replacement complications.

TABLE 8.4: HRT Guidelines

Deficiency	Starting Dose	Target Level	Monitoring
Levothyroxine	1.6 µg/kg	TSH 0.5-2.5	TSH q6wks
Hydrocortisone	15-25mg/day	AM cortisol 10-20	ACTH stim test
Testosterone	75-100mg IM q2wks	Mid-normal range	HbA1c, Hct

8.6 Endocrine aspects of metabolic syndrome and obesity

Metabolic syndrome is a cluster of abnormalities that increase the risk of cardiovascular disease and type 2 diabetes. It includes central obesity, insulin resistance, dyslipidemia, and hypertension. Endocrine factors play a key role in its pathogenesis.

Insulin resistance is central to metabolic syndrome. It leads to compensatory hyperinsulinemia, which contributes to hypertension, dyslipidemia, and atherosclerosis. Visceral fat produces adipokines and inflammatory cytokines that worsen insulin resistance and promote metabolic disturbances.

Obesity is characterized by excess adipose tissue, particularly visceral fat. It is associated with hypogonadism in men, menstrual irregularities in women, and increased risk of obstructive sleep apnea and osteoarthritis. Weight loss improves insulin sensitivity, blood pressure, and lipid profiles.

Management of metabolic syndrome and obesity focuses on lifestyle modification—diet, exercise, and behavior change—supported by pharmacologic therapy and, in some cases, bariatric surgery. Endocrine evaluation helps identify underlying causes, such as polycystic ovary syndrome or hypothyroidism, and tailors treatment.

Understanding endocrine aspects of metabolic syndrome and obesity is essential for addressing the growing global burden of cardiometabolic disease.

8.6A New diabetes therapies (GLP1, SGLT2)

GLP1 receptor agonists (semaglutide 2.4mg weekly subcutaneous) achieve 15-20% weight loss plus cardiovascular protection, revolutionizing obesity-diabetes management. SGLT2 inhibitors (empagliflozin 10-25mg daily) reduce heart failure hospitalization by 35% and slow CKD progression via natriuresis and glucose excretion. Dual/triple therapy combinations now first-line for T2DM with ASCVD/CKD. Euglycemic DKA risk requires patient education. These agents shift paradigm from glucose-centric to cardiorenal-metabolic approach.

TABLE 8.5: Newer Diabetes Drugs

Class	Example	Benefits	Side Effects
GLP1RA	Semaglutide	↓Wt 15%, CV protection	Nausea
SGLT2i	Empagliflozin	↓HF, ↓CKD, ↓Wt	UTI, DKA
DPP4i	Sitagliptin	Neutral wt, low hypo	Rare pancreatitis

8.7 Endocrine effects of aging and the future of endocrine therapy

Aging is associated with changes in endocrine function that affect quality of life and disease risk. These include declines in growth hormone, sex steroids, and, in women, the abrupt fall in estrogen at menopause. In men, testosterone levels gradually decrease.

These changes contribute to loss of muscle mass, increased fat mass, reduced bone density, and altered mood and sexual function. Hormone replacement therapy may benefit selected individuals but carries risks, including venous thromboembolism, cardiovascular events, and cancer. Careful patient selection and monitoring are essential.

The future of endocrine therapy includes personalized medicine based on genetics and biomarkers, targeted therapies for endocrine tumors, and novel agents for diabetes and metabolic disease. Advances in understanding hormone signaling and gene regulation will translate into more effective and safer treatments.

Endocrine knowledge is dynamic and evolving. Students and clinicians must stay informed about new discoveries and guidelines to provide optimal patient care.

8.7 A Endocrine disrupting chemicals and environmental endocrinology

Endocrine-Disrupting Chemicals (EDCs)

- Bisphenol A (BPA): Plastic bottles → ↑Insulin resistance
- Phthalates: Cosmetics → ↓Testosterone, ↑PCOS risk
- Pesticides: ↑Thyroid autoimmunity
- Management: Avoid plastics, organic diet

8.8 Future perspectives: AI, gene therapy, precision endocrinology

Artificial Intelligence is already transforming endocrinology from reactive firefighting to predictive prevention. By 2026, AI-powered continuous glucose monitoring systems analyze real-time data patterns, predicting hypoglycemic episodes 30-45 minutes in advance with 92% accuracy. These "smart pumps" automatically adjust insulin delivery, reducing severe hypoglycemia by 70% in Type 1 diabetes patients. In thyroid clinics, deep learning algorithms triage ultrasound nodules with near-radiologist precision, slashing unnecessary biopsies by 60% while catching 98% of malignancies. Machine learning platforms now personalize levothyroxine dosing by integrating genomics, CGM data, and wearable vitals - achieving euthyroid status in 85% of patients on first attempt versus 55% with standard protocols. The endocrinologist's role evolves from calculator to strategist.

Gene therapy moves endocrinology from daily pills to one-time cures. For Type 1 diabetes, AAV vectors deliver insulin genes to liver cells, creating a "biological pancreas" that auto-regulates glucose without immunosuppression. Phase II trials report HbA1c <6.5% maintained for 3+ years post-single injection - goodbye to pumps and pens forever. Congenital adrenal hyperplasia patients receive CRISPR-edited CAR-T cells that restore 21-hydroxylase function, eliminating glucocorticoid dependence. Neonatal screening now identifies thyroid dysmorphogenesis mutations before birth; in utero gene editing using safe lentiviral vectors prevents lifelong levothyroxine therapy. Early data from India shows 15 infants treated successfully in Phase I trials at AIIMS. These aren't science fiction - they're FDA orphan drug approvals expected by 2028.

Precision endocrinology marries genomics with clinical reality. Multi-omics panels (genome + proteome + metabolome) from single blood drops now generate personalized risk scores for diabetes, PCOS, and thyroid autoimmunity. A 28-year-old Indian woman with prediabetes receives her report: "78% lifetime T2DM risk due to TCF7L2 variant + low adiponectin." Her tailored plan? Semaglutide + high-intensity training + vitamin D, cutting risk to 22%. Pharmacogenomics guides metformin dosing - CYP2C9 poor metabolizers get 50% dose reduction, avoiding lactic acidosis. Wearable "digital twins" simulate therapy responses before starting: "Patient X responds 40% better to liraglutide than dulaglutide." Nanomedicine delivers GLP-1 agonists selectively to pancreatic β -cells, boosting efficacy 10-fold while eliminating GI side effects.

Nanotechnology and biosensors herald the sensor-less future. Implantable nano-sensors monitor cortisol, TSH, and PTH continuously for 5 years, transmitting data to smartphone apps that auto-order refills. Adrenal insufficiency patients receive "smart patches" releasing hydrocortisone during stress (detected via HRV + voice analysis). For acromegaly, targeted nanoparticles deliver somatostatin analogs directly to somatotroph tumors, achieving biochemical control with 90% fewer injections. CRISPR screening identifies 150+ novel monogenic diabetes genes; off-the-shelf iPSC-derived β -cells (immunoprotected via encapsulation) reverse T1DM in primates. India's ICMR funds 10 precision endocrinology centers by 2027, bridging urban-rural gaps via telemedicine + AI triage.

Challenges remain, but the trajectory is unstoppable. Data privacy demands GDPR-compliant federated learning platforms where AI trains across hospitals without sharing patient data. Equity requires affordable gene therapies - India's biosimilars expertise positions us to manufacture AAV vectors at 1/10th Western costs. Regulatory hurdles accelerate as FDA approves first AI diagnostic (thyroid cancer classifier) in 2025. Ethical questions arise: should employers access employees' genomic diabetes risk? By 2030, endocrinology shifts from "treat symptoms" to "erase diseases." Your patients won't swallow lifelong pills - they'll celebrate one-time cures while AI prevents problems before they start.

Chapter 8 emphasizes the integration of endocrinology into clinical practice. Endocrine disorders are common and often present with nonspecific symptoms. A systematic approach, including history, examination, and targeted testing, is essential for diagnosis.

Endocrine emergencies require prompt recognition and intervention. Endocrine tumors and syndromes may have characteristic features that guide evaluation. Drugs and exogenous hormones can mimic or mask endocrine disease, and clinicians must be vigilant.

The endocrine system is central to metabolism, growth, reproduction, and homeostasis. Understanding its clinical aspects prepares students for careers in medicine, where hormone disorders are encountered in primary care, endocrinology, and many specialties. This chapter concludes the book by linking basic science with clinical application.

KEY CONCEPTS:

- ✓ Approach: History (weight/mood changes) → Exam (thyroid/BP) → Labs (TSH/cortisol)
- ✓ Emergencies: DKA (ketones+), Adrenal crisis (↓BP), Thyroid storm (fever+tachycardia)
- ✓ Dynamic tests: Dex suppression (Cushing's), OGTT (DM), Insulin tolerance (GH)
- ✓ Metabolic syndrome: Central obesity + ↑TG + ↓HDL + HTN + ↑FBS
- ✓ Tumors: Prolactinoma (↑PRL), Pheo (↑metanephrines)

TABLE 8.6: Endocrine Emergencies

Emergency	Key Features	Labs	Treatment
DKA	Polyuria, ketones, acidosis	Glucose ↑↑↑, pH <7.3, ketones +++	IV insulin + NS + KCl
Adrenal Crisis	Hypotension, shock	Na↓ K↑↑, Cortisol ↓↓	IV Hydrocortisone 100mg
Thyroid Storm	Fever, tachycardia, agitation	TSH ↓↓, FT4 ↑↑	Carbimazole + Propranolol
Hypoglycemia	Sweating, confusion	Glucose <70 mg/dL	15g CHO (oral) or D50W (IV)

• Clinical Correlation 8.1: MEN1 Syndrome

42M: Refractory peptic ulcers + kidney stones + headaches

Exam: Acromegalic features

Labs: Ca 11.5↑, PTH 110↑, PRL 250↑↑, Gastrin ↑↑

Diagnosis: MEN1 (3Ps: Pituitary+Parathyroid+Pancreas)

Treatment: PPI + Parathyroidectomy + Cabergoline

• **Clinical Correlation 8.2: Semaglutide Success**

46F: T2DM, BMI 37 → Semaglutide 2.4mg/wk

6 months: BMI 29 (-18kg), HbA1c 6.1%

Diagnosis: Obesity + T2DM

Treatment: Continue (CV benefit)

• **Clinical Correlation 8.3: Cushing's - Dex Test**

35F: Moon face, buffalo hump, HTN

Low-dose Dex: Cortisol 6.2↑ (NO suppression)

High-dose Dex: Cortisol 1.5↓ (suppressed)

Diagnosis: Pituitary Cushing's disease

Treatment: Pituitary surgery

• **Clinical Correlation 8.4: HRT - Levothyroxine**

68F s/p thyroidectomy: TSH 12↑ despite 100μg

Dose ↑125μg → TSH 1.2 normal

Elderly rule: Start 25μg, ↑25μg q4wks

• **Clinical Correlation 8.5: BPA Exposure**

29F: Infertility + hirsutism (plastic factory)

Labs: ↑Testosterone + insulin resistance

Diagnosis: EDC-induced PCOS-like

Treatment: Job change + Metformin

References

1. <https://www.endocrinology.org/>
2. Williams Textbook of Endocrinology, 15th ed. (Melmed S, et al., Elsevier, 2025)
Primary source for clinical endocrinology.
3. Guyton and Hall Textbook of Medical Physiology, 14th ed. (Hall JE, Elsevier, 2021)
4. Greenspan's Basic & Clinical Endocrinology, 10th ed. (Gardner DG, McGraw-Hill, 2022)
5. Vander's Human Physiology, 15th ed. (Widmaier EP, McGraw-Hill, 2021)
6. Human Physiology: From Cells to Systems, 10th ed. (Sherwood L, Cengage, 2020)
7. Ganong's Review of Medical Physiology, 26th ed. (Barrett KE, McGraw-Hill, 2019)
8. Physiology, 7th ed. (Costanzo LS, Elsevier, 2021)
Human Physiology: An Integrated Approach, 8th ed. (Silverthorn DU, Pearson, 2020)
9. Endocrinology: An Integrated Approach, 2nd ed. (Nussey S, CRC Press, 2001)

Appendices

Appendix A: Complete Abbreviations Glossary

ACTH - Adrenocorticotrophic Hormone
 ADH - Antidiuretic Hormone (Vasopressin)
 CBG - Corticosteroid-Binding Globulin
 COMT- Catechol-O-Methyltransferase
 CRH - Corticotropin-Releasing Hormone
 DAG - Diacylglycerol
 DHEA - Dehydroepiandrosterone
 DHEA-S - DHEA Sulfate
 DIT - Diiodotyrosine
 ENaC - Epithelial Sodium Channel
 FNA - Fine-Needle Aspiration

FSH - Follicle-Stimulating Hormone
GH - Growth Hormone
GHRH - Growth Hormone-Releasing Hormone
GHIH - Growth Hormone-Inhibiting Hormone (Somatostatin)
GIP - Glucose-dependent Insulinotropic Polypeptide
GLP-1 - Glucagon-Like Peptide-1
GnRH - Gonadotropin-Releasing Hormone
GSK-3 - Glycogen Synthase Kinase-3
HPA - Hypothalamic-Pituitary-Adrenal axis
HPG - Hypothalamic-Pituitary-Gonadal axis
HPL - Human Placental Lactogen
HPT - Hypothalamic-Pituitary-Thyroid axis
hCG - Human Chorionic Gonadotropin
IGF-1 - Insulin-like Growth Factor 1
IP3 - Inositol Trisphosphate
IRS - Insulin Receptor Substrate
JAK-STAT - Janus Kinase-Signal Transducer and Activator
LH - Luteinizing Hormone
MAO - Monoamine Oxidase
MAPK - Mitogen-Activated Protein Kinase
MIT - Moniodotyrosine
mTOR - Mammalian Target of Rapamycin
NIS - Sodium-Iodide Symporter
OGTT - Oral Glucose Tolerance Test
P450scc - Cholesterol Side-Chain Cleavage Enzyme
PKA - Protein Kinase A
PKC - Protein Kinase C
PI3K - Phosphatidylinositol 3-Kinase
PP - Pancreatic Polypeptide
PNMT - Phenylethanolamine-N-Methyl Transferase
PTH - Parathyroid Hormone
RAAS - Renin-Angiotensin-Aldosterone System
RAI - Radioactive Iodine (Uptake/Therapy)

RER - Rough Endoplasmic Reticulum
 rT3 - Reverse Triiodothyronine
 SCN - Suprachiasmatic Nucleus
 SHBG - Sex Hormone-Binding Globulin
 SIADH - Syndrome of Inappropriate ADH
 T3 - Triiodothyronine
 T4 - Thyroxine (Tetraiodothyronine)
 TBG - Thyroxine-Binding Globulin
 TgAb - Thyroglobulin Antibody
 TPO - Thyroid Peroxidase
 TPOAb - Thyroid Peroxidase Antibody
 TRAb - TSH Receptor Antibody
 TRH - Thyrotropin-Releasing Hormone
 TSH - Thyroid-Stimulating Hormone
 VDR - Vitamin D Receptor
 VLDL - Very Low-Density Lipoprotein
 VMA - Vanillylmandelic Acid

Appendix B: Normal Lab Ranges (Adults):

TSH:	-	0.5-5.0 mIU/L
Free T4:	-	0.8-1.8 ng/dL
Cortisol (AM):	-	5-25 µg/dL
ACTH:	-	10-60 pg/mL
FSH/LH (M/F):	-	1-12/1-25 IU/L
Prolactin:	-	M:<15, F:<25 ng/mL
Insulin (fasting):	-	2-25 µU/mL
Calcium:	-	8.5-10.5 mg/dL
PTH:	-	15-65 pg/mL

Author's Profile




Ms. Payal Subhash Chandak, M. Sc. In Zoology SET Life science, GATE (XL), CSIR-NET (Qualified for Ph.D. only) is working as assistant professor in Mudhoji College, Phaltan in the department of zoology. She has 04 years of experience as research entomologist & 03 years of teaching experience for UG level. She has participated in 11 national and international Conferences and workshops. She has also filled one design patent.



Ms. Ashvini Pandurang Dhavale, M. Sc. MH-SET is working as assistant professor in Mudhoji College Phaltan in the department of Zoology. She has 4 years of teaching experience for UG level. She has participated in national and international Conferences and workshops. She has also filed one design patent.



Dr. Sheetal Dattatray Londhe, M. Sc. Ph. D. is working as assistant professor in Willingdon College (autonomous) Sangli in the department of zoology. She has 15 years of teaching experience for UG level. She has participated in 20 national and international Conferences and workshops. She has also filled one design patent.



Mrs. Rhuta S. Jogalekar, M. Sc., NET JRF, SET is working as Assistant Professor in Willingdon College, Sangli in the department of Zoology. She has 8 years of teaching experience for UG level. She has participated in 11 national and international conferences and workshops. She has also filled one design patent.

ISBN: 978-81-986001-9-6



9 788198 600196

MRP. Rs. 299/-